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Angiogenesis is a central process to both physiological and pathological aspects
of living organisms. Understanding the angiogenic system via the key mediator, vascular
endothelial growth factor (VEGF), has led to the development of biophotonic models
capable of monitoring how this process is programmed. The whole animal model tested
here is based on the involvement of angiogenesis in a wound healing environment. This
model proved to be functional as a system monitor but lacked the precision to yield
significant results between the biological compounds tested (estrogen, methoxychlor, and
relaxin). The in vitro model is based on angiogenesis in a cancer environment. This
model proved to be both a valid and functional way of monitoring the biological
compounds tested (CoCl2, epinephrine, and norepinephrine).
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CHAPTER I
INTRODUCTION

Life is the result of a gene driven synergy between an organism’s endogenous and
exogenous environments. This complex relationship manifests itself in all processes of
the biological world. Since man has become aware of the world around and within him,
his quest to understand these processes has driven him to develop unique techniques to
observe the different aspects of life.
Living tissues depend on oxygen and nutrients to nourish their growth and
development. Complex vascular networks deliver alimentative cellular nutrients
throughout an organism to different tissues and organs, by serving as conduits of blood.
The process of new blood vessel formation is referred to as angiogenesis and involves the
formation of new blood vessels from preexisting endothelial cells. Angiogenesis is
essential for the maintenance of life in a living organism and manifests itself in many
physiological processes of life including healing and maintenance of wounds and cancer
[1-3].
Wound healing and cancer are dependent upon angiogenesis which is governed at
a genetic level in large part by vascular endothelial growth factor (VEGF) [4] . The way
VEGF interacts with its endogenous and exogenous environments affects angiogenesis,
ultimately affecting processes such as wound healing and cancer. The need to understand
the temporal and spatial regulation of VEGF related to its role as primary regulator of
1

angiogenesis is fundamental in understanding physiological processes which rely on
neovascularization. Research in the areas of cancer, wound healing, and even
reproduction stand to benefit from models based on angiogenesis. The angiogenicity of
biological compounds is a concern of scientists for both physiological and pathological
reasons.
Advances in molecular and cell biology have led to the development of new
imaging methods which utilize light as a qualitative and quantitative method of
measuring biological incident. This technology has led to production of cell lines and
whole animals which aim at exploiting the synergy of physics and biology, known as
biophotonics. Gene expression monitored via biophotonic reporter systems is both
economical and compliant for use in both academia and industry. The advantage of this
technology is in that it provides dynamic, real time and temporal assessment of specific
gene(s) of interest in relevant physiological environments and can be employed in both in
vivo and in vitro systems.
The firefly luciferase enzyme has been extensively studied and its use as a
biophotonic reporter has become routine. Luciferase reporters can be utilized for a range
of biological purposes from indicators of promoter activity to donor systems for
bioluminescence energy transfer (BRET) [5]. Coupling the promoter region of genes
responsible for angiogenesis, i.e. VEGF and VEGFR-2, enables a mechanism to easily
monitor the system of neovascularization.
Basic research concerned with utilizing biophotonic modeling is warranted for
scientific verification purposes. This dissertation will discuss experiments involving the
development and utilization of biophotonic models on the angiogenic system. The
2

models developed and utilized in this dissertation are based on sound scientific logic as
well as physiological purpose.
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CHAPTER II
LITERATURE REVIEW

Blood Vessel Formation
Blood vessels are formed by two distinct processes, vasculogenesis and
angiogenesis. Vasculogenesis involves the de novo differentiation of endothelial cells
from mesodermal precursor angioblasts and mainly occurs during embryonic
development, whereas angiogenesis involves neovascularization from pre-existing blood
vessels. Once the developing embryo has formed a primary vascular bed or plexus
(vasculogenesis), additional blood vessels are generated by sprouting and non-sprouting
angiogenesis. This neovascularization is refined and remodeled into a functional adult
circulatory system [1]. Neovascularization is for the most part quiescent in the adult,
however it is essential for a few key physiological processes that are fundamental to the
maintenance of life. Angiogenesis is vital for continuation of life via manifestations of
new generations, by being essential for the cycling of the female reproductive tract.
Likewise, neovascularization through angiogenesis plays a major role in pathological yet
integral processes of life like, healing and maintenance of wounds and tumor growth and
survival [2]. Through the study of these different angiogenic dependent processes vast
amounts of knowledge has been discovered, unveiling the key players that mediate blood
vessel formation. Vascular endothelial growth factor (VEGF) is responsible for many
aspects of angiogenesis and will be discussed in detail in this dissertation.
5

VEGF and VEGF Receptors
In the 1980’s VEGF was identified both as vascular permeability factor (VPF),
and as vascular endothelial cell-specific growth factor [3-4]. Molecular cloning of these
two proteins clarified that these proteins were in reality the same protein encoded by a
single gene. Today this protein is referred to most commonly as VEGF [5]. Structurally
VEGF belongs to the VEGF-PDGF (platelet-derived growth factor) super-gene family.
This gene family consists of gene products in which eight cysteine residues are conserved
at the same position. The gene products function as dimers since two out of eight
cysteines form intramolecular S-S bonds that form three loop structures [6] ranging from
34 to 45 kD in size [7]. Members of this VEGF family include VEGF-A or simply
VEGF [8-9], placental growth factor (PIGF) [10-11], VEGF-B [12], VEGF-C
[13],VEGF-D [14], and VEGF-E [15-16]. The major splice isoforms of VEGF consist of
VEGF121, VEGF165, VEGF189, and VEGF206, where VEGF121 and VEGF165 are the best
understood and expressed at higher levels [17].
VEGF exerts its actions on cells by binding tyrosine kinase receptors. VEGF’s
receptors are vascular endothelial growth factor receptor-1 (VEGFR-1), vascular
endothelial growth factor receptor-2 (VEGFR-2), and vascular endothelial growth factor
receptor-3 (VEGFR-3) [18]. These receptors form a subfamily within the platelet derived
growth factor (PDGF) receptor class. They consist of seven immunoglobulin-homology
(Ig) domains, a transmembrane sequence and an intracellular portion containing a split
kinase domain [18].
VEGFR-1 was discovered when a novel tyrosine kinase receptor gene was
isolated from a placental cDNA library. Based on this gene’s structural similarity it was
6

first named Fms-like tyrosine kinase-1 (Flt-1) [19]. Later Flt-1 was found to have high
affinity for VEGF and was found to be the first receptor for VEGF, thus VEGFR-1 [20].
VEGFR-2 was first identified from a human endothelial cell cDNA library using primers
for the kinase domain of the known type III receptor kinases, thus it was first known as
KDR or kinase domain region. It was later proved that VEGF did bind KDR also known
as VEGFR-2 [21]. Similarly, VEGFR-3 was first isolated as Flt-4 and later recognized as
VEGFR-3 [22].
VEGF receptors are tyrosine kinases and follow the same signaling pathways.
The general cascade of signal transduction of tyrosine kinase receptors have several
steps: (1) ligand binding to receptor, (2) dimerization of receptor, (3) tyrosine kinase
activation, (4) receptor autophosphorylation, (5) adaptor binding and activation at the
autophosphorylation sites [23]. Much of the positive signal of VEGF, such as cell growth
is generated through VEGFR-2. Therefore, most of the signaling focus of researchers has
been on VEGFR-2. Through this research it was found that VEGFR-2 has a signaling
pathway somewhat different than that of other tyrosine kinases. Most tyrosine kinases
utilize the Ras-activation pathway leading to MAP kinase activation [23]. VEGFR-2 was
found to not use the Ras-activation pathway. Instead it was found that VEGFR-2 utilizes
the PLCγ-PKC pathway. PLCγ is bound to the autophosphorylated VEGFR-2, then
VEGFR-2 is tyrosine-phosphorylated and activated. This leads to PKC activation, then
Raf-1 activation leading to the MAP kinase cascade [24].
It should be mentioned that soluble forms of the VEGF receptors exist in nature as
well. These soluble receptors act as natural VEGF inhibitors and are formed from
alternative splicing of their respective mRNA’s [25-26].
7

VEGF’s role in embryonic development
The VEGF system is essential for proper embryonic development. Gene
knockout studies have revealed the vital role of VEGF and its receptors during
vasculogenesis and early angiogenesis in the developing embryo. A knock out of a single
VEGF allele results in the impairment of angiogenesis and vascular plexus formation
leading to the lack of embryonic growth and aberrant central nervous and cardiovascular
system development [27-28]. During embryonic development, the VEGF receptors are
expressed from the initial plexus formation onwards [29]. Mice homozygous for the
disrupted VEGFR-1 allele demonstrate normal development of angioblasts and
proliferation of endothelial cells, however organization of these cells into mature
functional blood vessels is aborted [30]. Interestingly, when only the tyrosine kinase
domain of VEGFR-1 is deleted, embryos develop normal blood vessels and survive. In
this instance the extracellular ligand binding domain of the receptor is left intact and still
is able to bind to VEGF. The observation that VEGFR-1 has a high affinity for VEGF
and a weak tyrosine kinase activity when bound to ligand, suggest that VEGFR-1
functions as a negative regulator of angiogenesis [31]. In VEGFR-2 knockout mice the
vascular plexus does not develop properly, vasculogenesis does not occur, and
hematopoietic cells fail to develop. This results in embryonic death and manifests the
requirement of VEGFR-2 for endothelial and hematopoietic differentiation and
proliferation [32]. VEGFR-3 seems to be necessary for vascular plexus development into
a hierarchy of large and small vessels. The lack of VEGFR-3 results in the aberrant
remodeling of the primary vascular network and abnormal endothelial cell organization
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leading to embryonic death. No major defects are noted in the differentiation of
endothelial cell or the formation of primary vascular networks [33].
Angiogenesis in the Adult
VEGF in Reproduction
VEGF and Estrogen
A very important process involving angiogenesis in the adult is the cycling of the
female reproductive tract. Like its involvement in angiogenesis associated with the
developing embryo, VEGF is crucial to angiogenesis associated with the female
reproduction cycle. The need for additional vasculature is continuously essential for the
cyclic evolution of the dynamic structures and for the constant repair of damaged tissues.
Associated with every estrus cycle is the development of follicles and corpora lutea of the
ovary. This requires the parallel development of vasculature networks to supply these
structures [34]. Proliferation of blood vessels in the uterus is required to replace vessels
lost or damaged from endometrium sloughing and at the site of embryo implantation [35].
Angiogenic waves within the female reproductive tract are coordinated and
associated with hormonal fluctuations during the estrus cycle. Estrogen [estradiol-17β
(E2)] is the main temporal and spatial mediator of cyclical neovascularization that occurs
in the ovary and uterus [2]. Estradiol 17 β is the primary stimulus of cyclic endometrial
growth and rapidly induces VEGF expression in the uterus in vivo [36-37]. Likewise, it
has also been demonstrated that E2 directly regulates VEGF gene transcription in primary
cell cultures from the reproductive tract [38], endometrial cancer cells [39], and breast
cancer cells [40]. In addition, the influence of E2 on VEGF is blocked by the antiestrogen
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ICI 182,780 [41]. These observations lead to the conclusion that VEGF is directly
regulated by E2 via ER pathways.
Estrogen interacts with VEGF through estrogen receptors (ERs). Estrogen
receptors belong to a super family of nuclear receptors which include receptors for
steroid and thyroid hormones [42]. There are two forms of the ER: alpha and beta (ERα
and ERβ). In the mammal these two forms are encoded by separate genes on different
chromosomes, unlike the progesterone receptor which is generated from alternate
transcription sites of the same gene [43]. ERs function dually as signal transducers and
transcription factors to regulate expression of target genes [44].

They have three

functional domains: 1) an N terminus which modulates transcription in a gene and cell
specific manner; 2) a central DNA binding domain consisting of two zinc fingers that
interact directly with the DNA helix; 3) and the ligand-binding domain [44-45]. When
appropriate ligands are not present, ERs are associated with heat shock proteins (HSPs).
Combined with a ligand, the ER experiences a conformational change resulting in the
HSP being released and the formation of a stable ER dimer [46]. These stable dimers
bind specific DNA sequences called estrogen response elements (EREs). These EREs
have the consensus sequence: 5’-GGTCAnnnTGACC-3’ [47]. The bound ER then
interacts with other cellular factors to either activate or deactivate transcription of the
target gene in a promoter and cell-specific process [48].
Two putative variant EREs were identified within the rat VEGF 5’-and 3’untranslated region based on ERE homology, binding to ERs in gel shift assays, and their
ability to mediate E2-induced reporter gene expression in ER-transfected HeLa cells [49].
However, another group linked E2 induction of VEGF expression to different variant
10

ERE located approximately 1.5 kb upstream of the transcriptional start site [2]. There is
no consensus of identification of EREs on the VEGF gene. Attempts to identify the sites
where estrogen receptors act to induce VEGF have produced inconsistent results [50].
Notwithstanding, most estrogen-regulated genes exhibit ERE sites in their promoter
regions [51], and these results confirm this conclusion.
VEGF and Relaxin
Other reproductive hormones influence VEGF as well, in particular relaxin
(RLX). Relaxin is a peptide hormone, produced by many mammals [52]. First identified
in 1926 by Fredrick Hisaw as a factor that stimulated growth and softening of the pubicsymphysis in the guinea pig [53], it was not until the 1970’s that purification and
sequence analysis was accomplished [54-55]. The premier of relaxin as exerting its
action on the female reproductive tract undoubtedly secured its role as a hormone of
pregnancy. However, now relaxin is accepted as having roles in many tissues across
species.
With renewed interest being sparked by its purification in the 70’s, relaxin’s
primary structure was able to be elucidated. Relaxin is a 6kDa polypeptide made up of
an A and B chain linked by two disulfide bonds [55], homologous to the structure of
insulin [56-58]. However, when relaxin is first synthesized it is produced first as a 23
kDa single-chain preprorelaxin consisting of the signal peptide, B-chain, connecting
peptide and A-chain. Upon further biosynthesis in the endoplasmic reticulum, a 19 kDa
prorelaxin is produced which gets further cleaved to produce the 6 kDa bioactive protein
[52].
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Two human relaxin genes were cloned and designated RLN1 and RLN2 [59].
RLN2 was shown to produce the circulating form of relaxin found in most mammals and
is the equivalent to human relaxin-2 (H2) [60]. Other members of the insulin-relaxin like
family of molecules exist in nature and will be mentioned in brief here to give heed to the
physiological importance this family of peptides encompasses. Other members include
relaxin-3 (RLN 3) or human relaxin-3 (H3), insulin-like peptide 3 (INSL3), insulin-like
peptide 4 (INSL4), insulin-like peptide 5 (INSL5), and insulin-like peptide 6 (INSL6).
RLN3 was shown to be almost exclusively expressed in the brain [61] and interestingly,
was shown to be the ancestral form of relaxins, insulin-like peptides, and insulin itself,
prompting this group of peptides to be called a family. However, the insulin-like
peptides do not share the binding motif of relaxin and therefore are not able to mimic the
actions of relaxin [60].
The relaxin receptor eluded scientists until the early 2000’s [62]. Until then,
relaxin had been shown to have binding sites in reproductive tissues such as the uterus,
mammary gland and placenta [63-65], as well as non-reproductive tissue like the heart
atrium and skin [66-67]. Given the similarities between insulin and relaxin, work done
on the INSL3 knockout mouse concluded that relaxin could stimulate both leucine-rich
repeat-containing G-protein-coupled receptors 7 and 8 (LGR7 and LGR8) and
consequently increase cAMP [62]. Eventually LGR7 and LGR8 were renamed RXFP1
(relaxin family peptide 1) and RXFP2 (relaxin family peptide 2) respectively, and
confirmed to be the relaxin receptors [60].
Relaxin is produced at peak levels by female reproductive tract tissues during
pregnancy. The tissue or organ that is the primary source of circulating relaxin varies
12

among species [52] The corpora lutea (CL) is the major source of relaxin in the pig,
cow, rat, mouse, and human [52, 68-71]. In other species such as the horse, cat, dog, and
rabbit the placenta is the major source of circulating relaxin [52, 72]. Secondary sources
of relaxin are common in animals as well, such as: the uterus in the pig, rat and rabbit, the
ovaries in the dog, and the decidua in the human. These secondary sources more than
likely act locally and do not significantly contribute to circulating levels [52].
Relaxin has copious effects on the reproductive system, which include growth and
preparation of the reproductive tract for pregnancy and parturition [52]. It has been
shown to have uterotrophic effects in a variety of animals. Rats exhibit a nearly doubling
of uterine wet weight when exposed to relaxin [73-74]. Treatment with RLX stimulated
a twofold increase in uterine weight as well as up regulating insulin-like growth factor
(IGF) in prepubertal gilts [75-76]. Likewise, it has also been demonstrated that relaxin
induces an increase in uterine weight and stimulation of endometrial angiogenesis in the
monkey [77-78].
Many of the uterotrophic effects of relaxin are similar to those of E2.
Interestingly, these uterotrophic effects may depend, in part, on crosstalk with the ER
signaling system. It is well documented that growth of the female reproductive tract is
sensitive to estrogen and relaxin [36, 74, 79]. The specific estrogen receptor antagonist
ICI 182,780 blocks the uterotrophic effects of RLX in the neonatal pig [80] and rat [79].
Relevant to this review is the fact relaxin effects VEGF expression. Anytime
remodeling and growth of the female reproductive tract occur, new blood vessels are
formed to supply the tissue with oxygen and nutrients [81]. In the macaque monkey,
relaxin has been shown that along with E2 treatment to stimulate new blood vessel growth
13

in the endometrium [77]. Multiple studies have shown that new blood vessel growth is
accompanied by up regulation of both VEGF mRNA and protein expression [36, 38, 8183]. Relaxin has been shown to specifically increase VEGF expression in human
endometrial cells in vitro, as well as causing heavier menstrual bleeding when given to
women exogenously. These observations led researchers to conclude that one of
relaxin’s physiological roles is to promote VEGF driven endometrial angiogenesis during
the menstrual cycle and early pregnancy [84].
As mentioned previously, relaxin has many roles outside of the female
reproductive tract. Summerlee and colleagues first demonstrated a non-reproductive role
of relaxin in 1984, when relaxin was shown to disrupt reflex milk ejection upon injection
into cerebral ventricles [85]. Since then, relaxin has shown to promote its actions in
tissues ranging from the heart and vascular system to tumors in both male and females
[86-87].
Relaxin’s ability to stimulate angiogenesis in tissues found outside of the female
reproductive was investigated in early clinical trials involving administering porcine
relaxin to patients with scleroderma or peripheral vascular disease [88]. In these studies
relaxin perpetrated healing of ischemic ulcers [89] and improvement of peripheral
vascular disease symptoms [90] by enhancing blood flow to ischemic sites. These studies
led researches to explore relaxin’s efficacy as an agent in wound healing. In a study
conducted by Unemori et al., the ability of relaxin to induce angiogenesis was tested
using the murine Matrigel system [88]. Matrigel is an extract of basement membrane
proteins that reconstitutes into a gel when injected into mice. Blood vessels grow into the
gel and can be quantified by measuring the amount of ingrowth [91]. Unemori et al.
14

found that the Matrigel/relaxin mixture induced significantly more vessel ingrowth than
vehicle alone. This study also showed upregulation of VEGF mRNA in response to
relaxin administration in vivo using Hunt-Schilling wound chambers implanted in rats
and in vitro using a macrophage cell line (THP-1) [88]. Relaxin’s influence of VEGF
during wound healing is of great importance because of the vital role that VEGF plays in
the process.
Wound Healing
Wound healing is a coordination of processes that involve soluble mediators,
extracellular matrix components, resident cell types, and leukocytes that work in a
temporally overlapping manner. These overlapping processes can be generalized and
divided into three main phases: inflammation, tissue formation, and tissue remodeling
[92]. When tissue injury occurs, it causes a disruption of blood vessels and subsequent
blood clot formation. The clotting is a result of surface activation of Hageman factor
(factor XII), tissue procoagulant factors released from damaged cells, surface membrane
coagulation factors, phospholipids expressed on activated platelets and endothelial cells
[93]. The clot serves as a temporary shield and as a matrix for cell migration. The clot
also serves as a reservoir for cytokines and growth factors that are released as platelets
degranulate [94]. Platelets from the clot secrete mediators such as platelet-derived
growth factor (PGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor
(EGF), fibroblast growth factor (FGF), and transforming growth factor-β (TGF- β).
These mediators recruit inflammatory cells to the wound site [95]. Neutrophils arrive
first (within minutes) in great numbers due to their abundance in circulation, soon to be
joined by macrophages which are phagocytically induced by binding to proteins of the
15

extracellular matrix via integrin receptors [96]. Neutrophils and macrophages cleanse the
wound area by phagocytizing foreign particles and bacteria as well as releasing proteases
that degrade damaged extracellular matrix [95]. Exhausted neutrophils are either
phagocytised by macrophages or extruded with the eschar, this usually occurs after a few
days [92]. Macrophages continue to accumulate at the wound site via recruitment by
blood-borne monocytes and release a variety of growth factors and cytokines including
VEGF [94].
Reepithelialization begins (hours after initial injury) to occur when the numbers
of inflammatory cells start to decrease. Fibroblasts, endothelial cells, and keratinocytes
take over production and release of growth factors [95]. Keratinocytes migrate into the
wound site to provide a protective covering that prevents fluid loss and a barrier against
bacterial invasion. VEGF gene expression is induced in wound margin keratinocytes by
leukocyte-derived cytokines, TGF-β, and hypoxia inducible factor 1 (HIF-1) [97-99].
Hypoxia inducible factor-1’s influence on VEGF will be discussed in detail later in this
review. The leading edge keratinocytes cut a path between the clot and healthy dermis by
activating various proteolytic enzymes such as plasmin via VEGF expression. Vascular
endothelial growth factor regulates the production of plasminogen activators (PA) which
produce plasmin from plasminogen [94, 100]. Epidermal cells from remnant skin
accessories, such as hair follicles, reestablish an epithelial barrier and aid in removing the
blood clot and damaged stroma from the wound site [101]. Interestingly, hair follicle
stumps act as epidermal islands allowing for multiple epidermal cell sources in the
wound site [102]. Epidermal cell migration is coordinated with cell metamorphosis.
This change in phenotype includes retraction and dissolution of tonofilaments, and
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desmosomes. Actin filaments also form in the peripheral cytoplasm. These changes
allow for lateral mobility of epidermal cells in the wound site [92]. The migrating
epidermal cells dissect the wound, separating eschar from healthy tissue [101]. One to
two days after injury epidermal cells at the wound edge begin to proliferate most likely
from a “free edge” effect. As reepithelialization proceeds basement-membrane proteins
(i.e. fibrin and fibronectin) are reestablished in a zipper-like fashion and epidermal cells
revert to their normal phenotype and firmly attach the underlying dermis [101, 103].
Granulation tissue begins to invade the wound area approximately four days after
initial wounding. This granulation tissue consists of new blood vessels, macrophages,
fibroblasts, and loose connective tissue [92]. The macrophages continue to be a major
source of growth factors that stimulate fibroplasias and angiogenesis. Fibroblasts
produce proteins responsible for constructing the new extracellular matrix that supports
the newly forming tissue and newly forming blood vessels Angiogenesis is necessary to
sustain the newly formed granulation tissue. Many molecules have been found to exhibit
angiogenic activity including, VEGF, TGF-β, angiogenin, angiopoietin, thrombospondin,
and HIFs [101]. VEGF released at the wound site by keratinocytes and macrophages acts
in a paracrine and autocrine manner on wound edge capillaries. Here, VEGF aids in the
permeability of the wound site vessels, interestingly VEGF was originally referred to as
vascular permeability factor (VPF) [3]. The newly severed vessels continue to leak
plasma proteins several days after the initial trauma. The continued vascular
hyperpermeability helps maintain an environment which favors ongoing granulation
tissue deposition [98].
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Migration and mitogenic stimulation of endothelial cells is essential for
angiogenesis. VEGFR-1 and VEGFR-2 are upregulated in endothelial cells and are
activated by VEGF to stimulate integrins at the tips of sprouting capillaries, thus
enhancing endothelial cell migration (VEGFR-1) and proliferation (VEGFR-2). The
VEGF cascade also causes the production of proteases to aid in capillary invasion [97,
104]. Aside from endothelial cells from pre-existing blood vessels, endothelialization
also is carried out by recruitment of bone marrow-derived endothelial progenitor cells
(EPC). Endothelial progenitor cells can be categorized as embryonic angioblasts and are
able to mature into endothelial cells which are VEGFR-2 positive [105]. Endothelial
cells first assemble as solid vessels without a lumen. Then with the aid VEGF induced
integrin expression vessels acquire lumen and grow in length [94, 97]. Eventually the
granulation tissue is remodeled, and the end result is collagen rich scar.
Estrogen and Skin
Skin is a tissue with a plethora of functions including protection against infection
and ultraviolet light, thermoregulation, controlling of water balance, and as an endocrine
organ [48]. Of particular interest in VEGF’s involvement in wound site angiogenesis is
the hormone estrogen. To better understand estrogen’s role in this process, it is first
better to understand estrogen’s actions on the skin. Estrogen affects various components
of skin tissue. Studies have shown that estrogen can suppress sebaceous gland activity
[106] and hair growth [107-108]. It has long been recognized that estrogens stimulate the
synthesis, maturation, and turnover of collagen in rats and guinea pigs [109-110]. In
mice, estrogen has been found to increase the synthesis of hyaluronic acid in skin [111].
It has also been recognized for some time that estrogens play a role in the maintenance of
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human skin. This is most noted in postmenopausal women where there is a loss in
collagen content and quality, a decrease in skin thickness, and loss of vascularization
[112]. Studies using topical application of estrogen show a rebound in these above
mentioned parameters [113-114]. Of course estrogen’s actions could only be possible
with the presence of estrogen receptors, and time and time again skin has been shown to
possess estrogen receptors [115-118].
Estrogen has been implicated in wound healing as well. In the elderly wound
healing is severely impaired and estrogen has been found to be the most potent regulator
of age-associated delay in human wound healing by showing that the differences in gene
expression between elderly and young human wounds are almost exclusively estrogen
regulated [119]. Likewise topical estrogen has been shown to increase the extent of
wound healing in the elderly by reducing wound size and stimulating matrix deposition in
part by increasing TGF-β1 levels and decreasing macrophage migration inhibitory factor
(MIF) [120-122]. In the rat estrogen has been shown to play a role in facilitating penile
healing via up-regulation of VEGF levels [123].
Estrogen’s influence on the skin and in wound healing is undeniable. So it stands
to reason that compounds and chemicals acting as estrogens could alter or interfere with
the aforementioned estrogen influenced systems.
Endocrine Disruption
The U.S. Environmental Protection Agency (EPA) defines an endocrine disruptor
as “an exogenous agent that interferes with synthesis, secretion, transport, metabolism,
binding action, or elimination of natural blood-borne hormones that are present in the
body and are responsible for homeostasis, reproduction, and developmental process”
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[124]. Rachel Carson’s publication of Silent Spring in 1962 brought the concern that
environmental chemicals acting as endocrine disruptors could be impacting wildlife and
human health to the mainstream [125]. Substantial evidence has accumulated since
illustrating the hormone-like effects of environmental chemicals in fish, wildlife, and
humans [126]. Exposure to these chemicals will increase significantly, as the world
becomes more industrialized. Ailments such as reproductive anomalies, hormone-linked
cancers, and metabolic disorders including obesity have been linked to environmental
chemicals via endocrine disruption [127]. This has created a global concern among
scientist, industry, government regulators, policy makers, and private organizations alike.
It is a necessity for these entities to continue to fund research related to endocrine
disruption so new methods and breakthroughs can be established to help maintain a
homeostasis between man and environment.
Molecules identified as endocrine disruptors are very diverse and include
phytoestrogens, fungicides, industrial chemicals [polychlorinated biphenyls (PCBs),
polybrominated biphenyls (PBBs), dioxins], plastics [bisphenol A (BPA)], and pesticides
[methoxychlor, chlorpyrifos, dichlorodiphenyl-trichloroethane (DDT)], [128]. Many of
these chemicals natural and synthetic are estrogenic in nature causing them to exhibit the
deleterious effects of endocrine disruptors [129].
Pesticides are used worldwide for the control of agricultural and indoor pests
[130]. The widespread use and misuse of these chemicals has created an awareness of
the potential health hazard to the environment and concern relating to the protection of
the consumer from residues in food [131]. Pesticides can be grouped into families based
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on their respective chemical makeup. The main families of insecticides include
organochlorines, organophosphates, carbamates, and pyrethroids [132].
Dichlorodiphenyltrichloroethane (DDT), an organochlorine insecticide, has been
banned in the US and most developed countries since the 1970s because of its known
toxicity to the environment [133]. Methoxychlor (MXC) is an organochlorine insecticide
widely used as a substitute for DDT [134]. Methoxychlor [1,1,1-trichloro-2,2-bis(4methoxyphenyl)ethane] aka dianisyltrichlorethane, dimethoxy DDT, and DMDT, is a less
toxic analog of DDT [135]. It is a broad-range insecticide used on fruits, vegetables,
trees, gardens, forage crops and livestock [135]. MXC has been reported to be found in
1.2% of composite food samples in the US [136]. Current data from the Agency for
Toxic Substances and Disease Registry (ATSDR) indicate that 0.001 to 0.004 mg/kg of
MXC is present in dairy products, grains, fruits, and vegetables; while higher levels
ranging from 10 to 120mg/kg are present in fish [137].
Methoxychlor is considered safe for ubiquitous use because of its low acute
toxicity (rat oral LD50 6,000mg/kg) [138]. MXC is estrogenic in vivo yet its affinity for
the ERα is 10,000 times less than 17β-estradiol [139]. However, MXC is readily
metabolized by the liver to the estrogenic metabolite, 2,2-bis(4-hydroxyphenyl)-1,1,1trichloroethane (HPTE), which is a very effective competitor of the estrogen receptor
[138, 140].
The estrogenic effects of methoxychlor and its metabolites are demonstrated in
the estrogen sensitive female reproductive tract. Female reproductive development is
affected by MXC with varying degrees of severity. Neonatal mice treated with
methoxychlor were observed to have precocious vaginal opening, persistent vaginal
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cornification, increased uterine weight, and epithelial hypertrophy of the vagina and
uterus [141]. Chapin and colleagues have described changes in the reproductive,
immune, and nervous system function in juvenile mice exposed to methoxychlor [142].
Similarly, Alm et al. demonstrated MXC’s embryotoxicity [143]. Molecular studies with
ovariectomized rodents have also shown that MXC regulates many of the same uterine
proteins as E2 including epidermal growth factor [144], ER [145], and VEGF and
VEGFR-2 [146]. Interestingly, these proteins are also involved with angiogenesis.
Dwivedi and Tabbert realized the potential for methoxychlor to interfere with an
angiogenic process such as cancer and investigated the effect of MXC on skin tumor
development, but found no correlation between methoxychlor and tumor development
[131]. It remains to be seen what if any effect methoxychlor can have on angiogenic
processes.
Cancer
Cancer is the second leading cause of death in developed countries next to heart
disease and the third leading cause of death in undeveloped countries next to heart
disease and diarrhoeal diseases [147]. The National Cancer Institute estimates that
approximately 11.1 million Americans with a history of cancer were alive in January
2005. The estimated number of deaths in America alone for 2009 was 562,340. Cancer
accounts for nearly 1 of every 4 deaths in the US and 1 in 8 deaths worldwide. Among
cancer related deaths, lung cancer is the leading killer in both men and women followed
by prostate cancer in men and breast cancer in women [148].
Cancer is caused by exogenous factors such as tobacco smoking, chemical
exposure, radiation, and infectious organisms. As well as endogenous factors such as
22

inherited mutations, hormones, immune system conditions, and metabolism cause
mutations [147]. Cancer is characterized by uncontrolled cellular growth via loss of
molecular growth controls and loss of contact inhibition. A cancer cell has the ability to
invade other tissues and in some cases the ability to spread to other locations in the body
(metastasis). All cells increase in number by going through the cell cycle. The cell cycle
contains checkpoints in which the cell is either diverted out of the cell cycle or undergoes
apoptosis. In brief, disruptions in cell cycle checkpoints via genetic mutations or
aberrations cause a cell to lose its growth regulation giving rise to cancer [149].
The process of cancer development is termed carcinogenesis. Experiments done
using a mouse skin model show that carcinogenesis can be divided into three main stages:
initiation, promotion, and progression. Initiation involves a carcinogen (cancer causing
agent) creating genetic mutations in a tissue’s stem cells. Promotion is characterized by
clonal expansion of initiated cells which gives rise to tumors. The third stage,
progression, is when these tumors become invasive. Progression can be spontaneous or
caused by increased exposure to carcinogens [150]. In summary the genetic mutation
induced alterations in cellular physiology which mediate malignant growth are: (1) selfsufficiency in growth signals, (2) insensitivity to growth-inhibitory signals, (3) evasion of
programmed cell death, (4) replicative immortality, (5) sustained angiogenesis, and (6)
tissue invasion and metastisis [151].
Tumors require the formation of supporting stroma and vascular supply if they are
to grow more than 1-2mm [149]. Angiogenesis is required to form blood vessels to
supply the tumor with nutrients and a means for gas exchange and waste disposal.
Tumors exhibit various forms of angiogenesis other than classical neovascularization.
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These alternative forms include intussusceptive vascular growth, co-option, formation of
mosaic vessels, and vasculogenic mimicry. During intussusceptive vascular growth,
interstitial cells form a column in the lumen of an existing vessel thereby yielding two
vessels. This process involves the rearrangement and remodeling of endothelial cells
rather than proliferation. This process is metabolically efficient since endothelial cell
proliferation and basement membrane degradation are not required [152]. Co-option is
when a developing tumor surrounds vessels in the tissue or organ of origin and
incorporates the vessels into it. This process is important to tumors that are associated
with a highly vascularized organ such as the lung [153]. Sometimes tumor cells disguise
themselves as endothelial cells and along with native endothelial cells form the luminal
surface of capillaries resulting in a mosaic vessel [154]. Vasculogenic mimicry occurs
when vascular channels are formed from extracellularmatrix-rich tubular networks which
lack endothelial cells but contain circulating red blood cells. Observations of this
phenomenon suggest that aggressive cancer cells generate vascular channels that
facilitate tumor perfusion independent of normal tumor angiogenesis [155].
Tumor vessels exhibit abnormal morphology compared to normal vessels.
Tumors grown in rats exhibited capillaries five times larger in diameter than those of
normal tissue [156]. Tumor vessels often develop into disorganized bundles with many
vascular sprouts. This abnormal organization leads to chaotic blood flow in tumors
[157].
Transgenic model studies have shown that tumors switch to an angiogenic
phenotype early on in its development and that this switch is rate limiting in terms of
tumor progression [158]. The relationship between tumors and angiogenesis is further
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supported by a study which found cancerous human breast tissue samples to be 30%
more angiogenic than normal human breast tissue [159]. Tumor induced angiogenesis
occurs as a result of the complex networking of a plethora of cellular factors which
regulate the growth and differentiation of endothelial cells. Among these regulators is the
VEGF family of proteins.
As a tumor grows, cells of the inner mass become separated from native vascular
stroma and cellular diffusion becomes impossible. The result is hypoxia (low 02
concentration) of the inner cells, which is a major stimulus for angiogenesis [160]. Many
genes are known to be regulated by hypoxia including VEGF [161]. Furthermore,
hypoxia has been demonstrated to upregulate VEGF expression in tumors [162-164].
The degree of tumor angiogenesis is related to clinical outcome, suggesting that
certain angiogenic factors correlate with tumor aggressiveness [165-167]. VEGF has
been found to be closely related to poor prognoses in various cancers [168-172], because
of its involvement in tumor angiogenesis. A meta-analysis of VEGF levels in healthy
subjects and cancer patients revealed that plasma VEGF levels are several times higher in
cancer patients [173]. Inhibition of VEGF signaling and expression becomes very
attractive in terms of anti-cancer therapy. Studies have shown that anti-VEGF antibodies
can inhibit both angiogenesis and tumor growth [174]. The manner in which VEGF is
influenced by endogenous hormones becomes increasingly interesting and important in
terms of cancer and tumor progression.
Oxygen Sensing
Physiological adaptations to hypoxia are essential for organisms to maintain
adequate oxygen levels required for life. These adaptations manifest themselves in a
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variety of ways including increased production of erythropoietin (EPO) and VEGF which
lead to increased red blood cell formation and stimulation of new blood vessel growth,
respectively [175]. Oxygen responsive genes are regulated through accurate sensing of
O2 and transduction of the signal that activates hypoxia inducible factor-1 (HIF-1) [176178].
Hypoxia transcriptionally induces hypoxia inducible factor-1 (HIF-1), the
transcription factor responsible for cellular responses to low oxygen levels [179-180].
HIF-1 acts on a hypoxia response element (HRE) located in the promoter region of target
genes such as EPO and VEGF [181-182], and are approximately 50 base pairs in length
[183]. HIF-1 was originally discovered in Hep3B cells as a nuclear factor induced by
hypoxia with binding affinity to an enhancer in the promoter region of the erythropoietin
gene [184]. HIF-1 binding of this enhancer region allowed for its initial purification and
cloning [185]. HIF-1 is a heterodimer consisting of an α and β subunit (HIF-1α and HIF1β), [180]. Both subunits were found to belong to the basic helix-loop-helix PAS
(Per/Arnt/Sim) family of proteins, where HIF-1β being characterized as aryl hydrocarbon
receptor nuclear translocator (ARNT)[185-186]. Under normoxic conditions, HIF-1β is
constitutively expressed in mammalian cells. However, HIF-1α is rapidly degraded by
the von Hipppel-Lindau protein (pVHL) targeting it for the ubiquitin-proteasome system
[187-188]. Under normoxic conditions pVHL associates with the oxygen-dependent
degradation domain (ODD) of HIF-1α which undergoes an oxygen and iron dependent
prolyl hydroxylation, leading to ubiquination and degradation [189]. This degradation
results in a cellular half-life of approximately five minutes under normoxic conditions.
Under hypoxic conditions, HIF-1α does not associate with pVHL and is stabilized and
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translocates to the nucleus and dimerizes with HIF-1β in addition to coactivators such as
p300/CBP, to form the heterodimeric HIF-1 complex which binds to the HRE causing
target gene transcription [190-191].
Hypoxia can be simulated by exposing cell cultures to cobalt chloride CoCl2 [179,
192-194]. CoCl2 simulates hypoxia by stabilizing the cytosolic HIF-1α [195]. CoCl2
stabilizes HIF-1α by inhibiting the proteases that degrade HIF-1α in the presence of O2
[196]. Cobalt and other metals such as nickel are thought to stabilize HIF-1α by
inhibiting the prolyl hydroxylase domain (PHD) containing enzyme through Fe2+
substitution [197].
Stress and Cancer
The hypothalamic-pituitary-adrenocortical (HPA) axis and sympathetic nervous
system are the physiological mediators of the neuroendocrine stress response through
compounds such as cortisol, neuropeptides, and catecholamines [198-199]. These
compounds trigger a variety of physiological responses meant to be beneficial to an
organism via initiating the “fight or flight response”. Thus these compounds, in acute
situations, are necessary for an organism’s survival [199]. However, prolonged exposure
to these same stress mediators have been shown to initiate pathological processes and
exacerbate diseases, such as cancer [200].
Catecholamines (CAs) are organic compounds consisting of a benzene ring with
two hydroxyl groups and an opposing amine side chain. The major CAs used by the
nervous system are dopamine (DA), epinephrine (E), and norepinephrine (NE) [201-202].
Catecholamines are mainly produced by chromaffin cells of the adrenal medulla and
postganglionic fibers of the sympathetic nervous system [203]. Synthesis of
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catecholamines begins with the amino acid tyrosine. The synthesis pathway of
catecholamines from tyrosine proceeds as follows: Tyrosine undergoes an hydroxylation
to form L-DOPA, L-DOPA undergoes a decarboxylation to form dopamine, dopamine is
then transported inside secretory vesicles of the postganglionic nerves where a
hydroxylation occurs to form norepinephrine, in the adrenal medulla this pathway goes
one step further to form epinephrine from the methylation of norepinephrine [204].
There is growing evidence that there is a link between psychological factors and
the incidence and progression of cancer [205-208]. Increased levels of catecholamines
associated with stress are interestingly reversed and actually lower in patients associated
adequate social support [209-210]. This close association between stress and cancer
progression is further supported by studies which show an improved cancer outcome
associated with adequate social support [211-215]. Studies in the field of
psychoneuroimmunology have shown that psychophysiological effects of stress on the
endocrine system can affect cellular immune function [206], which in turn can modulate
the growth of certain tumors [207]. Likewise it has been demonstrated that stress
induced catecholamine activity can affect integral aspects of tumor progression such as
angiogenesis via VEGF [208, 210, 216-217]. It has also been demonstrated that NE
mediates VEGF production through β-ARs [206, 218-219].
Epinephrine and norepinephrine exert their actions via adrenergic receptors. Two
main families of adrenergic receptors exist, α-adrenergic and β-adrenergic [220].
Generally speaking, α-adrenergic receptors are negatively coupled with adenylate cyclase
and β-adrenergic receptors are positively coupled with adenylate cyclase, which means α
receptors usually have inhibitory functions and β receptors usually have excitatory
28

functions [221]. The adrenergic receptors (AR) can be further divided into subtypes: the
α-AR family includes the α1a, α1b, α1d, α2a, α2b, and α2c subtypes while the β-AR family
includes the β1, β2, and β3 subtypes [202]. These subclassifications of ARs are based on
their respective physiological actions and second messenger systems as well as their
differential affinities for various ligands [221]. Interestingly, many solid epithelial
tumors express ARs [210, 221-225]. Stress’ involvement in cancer physiology is and
will be an important avenue of research with the potential for unlocking new anticancer
therapies and drugs.
Bioluminescent Tools in Research
Bioluminescence is the generation of light by living organisms as the result of an
exoergonic reaction where chemical energy is converted to light energy. Many nonmammalian species are equipped with the bio-machinery to carry out this process [226227]. Bioluminescent organisms are found throughout nature and constitute a diverse set
of species including bacteria, dinoflagellates, fungi, fish, insects, shrimp, and squid [228].
This unique phenomenon exists in nature for three general reasons: offense (luring,
baiting), defense (startle, camouflage), and communication (courtship, mating) [229]. In
recent years bioluminescence has found its way to the laboratory as a valuable tool in
many areas of research.
Over the years scientists have learned much about the bioprocesses that enable
bioluminescence to occur. Bioluminescence is generated by an enzyme-catalyzed
chemiluminescence reaction. The enzymes that catalyze these reactions are called
luciferases and in most cases act on substrates called luciferins [228]. The luciferin29

luciferase reaction is found in many organisms throughout nature, yet there are five basic
reaction types:


Bacterial luciferin is a reduced riboflavin phosphate (FMNH2) that is
oxidized by a luciferase associated with a long-chain aldehyde and O2.



Dinoflagellate luciferin is closely related to the porphyrin of chlorophyll.
This luciferin is conformationally shielded from luciferase at basic pHs
and becomes oxidizable at more acidic pHs.



Luciferin from the ostracod Vargula is called vargulin.



Coelenterazine is widely utilized luciferin in many marine taxa.
Coelenterate luciferase activity is controlled by Ca2+ concentration and is
closely related to calmodulin.



Firefly luciferin is found exclusively in fireflies and requires



ATP as a co-factor to convert it into an active luciferin [229-230].

Luciferase (61kDa) isolated from the firefly (Photinus pyralis) has been
extensively studied and its role in the catalyzation of biophotonic light has been
established. The reactions catalyzed by firefly luciferase are:

Figure 2.1

Luciferase Reaction

In the first reaction an enzyme-bound luciferyl-adenylate is formed. During the
second reaction the luciferyl-adenylate goes through an oxidative decarboxylation. The
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products of this second reaction are CO2, oxyluciferin, AMP, and light. The light
produced from the reactions is proportional to the amount of luciferase in the reaction
mixture. The emitted light from the reaction decays to approximately 10% of the zenith
level within 1 minute. The remaining low level of light decays at a much slower rate
[231-233].
Advances in molecular and cell biology techniques have led to the development
of new imaging methods using bioluminescence as a reporter. The number of laboratory
techniques and applications using luciferase has exploded with the advent of gene cloning
and the ability to transform genes into heterologous hosts such as single cells and whole
organisms [234]. In fact, from 1988 to 2000, thirty photoprotein fusions and conjugates
were reported [229]. These luciferase fusions and their more recent versions have taken
on four generalized tasks: (1) reporting of promoter activity through target gene
promoter-luciferase fusions, (2) indicating ion concentration, (3) molecular reporting of
circadian rhythms, and (4) serving as the donor system in bioluminescence resonance
energy transfer (BRET) [234]. This review will focus on target gene promoter-luciferase
fusions.
Cellular Bioluminescence
Cellular bioluminescence was put on the map when in 1985 a group of
researchers showed that the bacterial luciferase operon luxCDABE from Vibrio fisheri
could be expressed in E.coli without the need to add the lux substrate because of the
presence of the full operon [235]. This led the way to applications such as antibiotic
susceptibility testing [236], environmental health assays [237], and food contamination
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assays [238]. Eventually the lux operon was expressed in eukaryotic organisms such as
plants and yeast [239].
Ultimately, imaging eukaryotic luciferase expression in eukaryotic cells and cell
cultures made its way into laboratories. In 1987 Keller et al. demonstrated firefly
luciferase could be expressed in mammalian cells by transfecting CV-1 cells (a monkey
kidney cell line) with the plasmid pRSVL, which contains the full-length luciferase
cDNA [240]. Transient expression of luciferase fusion proteins in mammalian cells has
been demonstrated many times since including specific promoter driven gene expression
in many cell types. The rabbit collagenase gene promoter was fused to the luciferase
gene and expressed the smooth muscle cell line Rb-1 and collagenase gene expression
was shown to increase after injury [241]. Estrogen-regulated gene expression in breast
cancer cells was able to be monitored real-time in response to 4-Hydroxytamoxifen and
phytoestrogens by transiently transfecting breast cancer cells with an estrogen response
element driven luciferase reporter plasmid [242-244].
Many stably transfected cell lines have been developed as well. One such line
used in these doctoral studies was developed by Xenogen now Caliper Life Sciences to
monitor angiogenic signaling via the human VEGF/luciferase fusion reporter (hVEGFluc). The 2.3 kb human VEGF promoter was fused to the Photinus pyralis (North
American firefly) luciferase gene and stably transfected into a metastatic human prostate
adenocarcinoma cell line (PC-3M) [245]. This cell line makes it possible to conduct
experiments concerning how VEGF is influenced in a prostate cancer environment.
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Whole Animal Bioluminescence
Reporter gene fusions have been applied to whole animal research as well. Whole
animal fusion reporter gene applications were limited to ex vivo methods in the
pioneering stages. These methods involved excision of tissue and assessing levels of the
reporter molecule in the tissue samples [246-247]. Methods such as these require
eliminating animals to obtain tissue samples thus negating fully understanding gene
regulation in a living system. Furthermore, to obtain temporal analysis of gene
expression large numbers of animals have to be eliminated at each time point for
statistically relevant data, which is costly and inefficient [247].
Since the advent of luciferase reporter imaging researchers have been fine tuning
and developing techniques in pursuit of the penultimate goal of non-invasively
monitoring gene expression real-time in living whole organisms; with the plethora of
ultrasensitive photon detectors this goal can be accomplished. The advantages of this are
that it provides dynamic, real-time assessments of the physiological event(s) under study
and, in the case of in vivo animal models, can dramatically reduce the number of animals
needed to conduct the study [248]. This was first accomplished in transparent organisms
such as drosophila, fish, and mouse embryos [249-251]. Soon, with advent of photon
sensitive charge-coupled device (CCD) cameras, noninvasive monitoring of transgenic
bacterial pathogens in non-transparent animals, such as mice and neonatal pigs, could be
accomplished [252-254]. Ex-vivo methods of monitoring bacterial lux expression have
been applied in our lab to large adult animals such as sheep, pigs, cows, and horses [255258]. Non-invasive monitoring of gene expression in adult large animals is met with the
obstacle of a thick adult dermis. Our lab has tried to circumvent this obstacle by using
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optical clearing agents to make the adult dermis more transparent [259]. However, realtime gene expression in a living organism is not fully realized until the routine production
of luciferase reporter-transgenic animals.
Transgenic Animals
A transgenic animal is an animal that has within its genome gene sequences that
have been inserted by laboratory techniques [260]. Three main methods are used to
deliver transgenes to a developing organism, thus creating a transgenic animal. The
main method used is microinjection of DNA fragments into the pronuclei of one-cell
embryos, which are then introduced into a surrogate to complete development. A second
method is to expose cleavage-stage embryos to engineered retroviruses in vitro then
return the retrovirus exposed embryo to the uterus of a surrogate for development. A
third method utilizes embryonic stem (ES) cells by introducing a manipulated stem cell
back to a developing blastocoels where it colonizes the embryo [261]. Transgenes are
ideally passed from parent to progeny in which case the propagation of the new
bioengineered organism can be achieved.
The main method of microinjecting transgenes into the pronuclei of one-cell
embryos was first accomplished in 1980 [262]. This method has proved to be limitless in
the number of possibilities it can provide agricultural and biomedical research, yet it does
have its drawbacks. The success of integration by microinjection is low, ranging from
3% in mice, rats, and rabbits to 1% in cattle and sheep [263]. Microinjection leads to the
random integration of the transgene into the recipient’s genome, resulting in a mosaic in
which not all cells of the animal contain the transgene or the same number of copies of
the transgene. Mosaicism can also lead to high variability in transgene expression
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between animals as well as chromosomal position effects [264]. Testing multiple lines of
animals for transgene integration is necessary when using this technique, which can
prove costly both financially and temporally.
Retroviral infection offers the advantage of technical ease of introducing the
transgene into the embryos at various stages of development. Additionally it has been
demonstrated to be easier to isolate flanking DNA sequences of a proviral insert than
those flanking a DNA insert from pronuclear microinjection. This offers a great
advantage when attempting to identify the host gene that has been disrupted by the viral
DNA. The drawbacks of this method are the size limitations for transduced DNA and
problems arising when trying to reproduce transduced gene expression in the animal
[265].
Utilizing embryonic stem cells and homologous recombination to create
transgenic animals provides a means to systematically alter an animal’s genome [266].
Embryonic stem cells are derived from the inner cell mass of a blastocyst and can remain
undifferentiated and pleuripotent under certain tissue culture conditions. When these ES
cells are introduced into a blastocyst in utero they will transmit their engineered genome
to the developing embryo creating a chimeric adult with an altered genome, which can
then transmit its altered genome to its offspring [267]. Homologous recombination
allows for a gene of choice to be altered in a predetermined way; this is also known as the
“knock-in” technique. Using this approach a gene of interest such as a reporter gene like
luciferase can be knocked in the exact spot in the native genome and be placed under
control of the endogenous gene’s regulatory elements [268]. This technique of creating
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transgenic animals offers the most potential to researchers without the limitations of the
previously described methods.
Charge-Coupled Device Cameras
Charge-coupled device (CCD) cameras have become the quintessential method of
imaging low levels of light emission. Imaging with these cameras involves three stages:
(1) interaction of a photon with the photosensitive surface, (2) storage of the liberated
charge, (3) readout or measurement of the stored charge. CCDs contain arrays of silicon
photoconductors that enable transfer of the photon signal to the output amplifier.
Individual pixels absorb photons in a region known as the depletion layer. This photon
absorption results in the discharge of an electron which has a corresponding positively
charged hole in the silicon lattice. These charges are collected and transferred to the
readout amplifier where they are converted to a voltage which is quantifiable [269].
When the light signal is very low, the process of binning can be applied to the
pixels which may improve the photonic signal. Binning is the process by which the
signals from several adjacent pixels are pooled and treated as if they are one large pixel.
Binning trades of resolution for sensitivity [269].
CCD cameras are often cooled; in the case of the CCD in the IVIS 100 used in
these studies, liquid nitrogen is used to cool the camera. Cooling a CCD camera helps
reduce the electronic noise that is picked up by the chips. Another benefit from cooling
the camera is an improvement of the charge transfer efficiency (CTE). This is relevant
because each time a charge is shifted along the transfer channels from the pixels to the
amplifier, it is possible that some charge may get left behind; if this occurs the image is
blurred. Cooling a CCD typically results in negligible charge loss [269].
36
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CHAPTER III
METHOXYCHLOR EXPOSURE DOES NOT ALTER VASCULAR ENDOTHELIAL
GROWTH FACTOR RECEPTOR-2-LUC REPORTER GENE EXPRESSION IN A
TRANSGENIC MOUSE WOUND MODEL

Abstract
Vascular endothelial growth factor (VEGF) is essential for normal vascular
growth and development during wound repair. VEGF is estrogen responsive and capable
of regulating its own receptor, vascular endothelial growth factor receptor-2 (VEGFR-2).
Several agricultural pesticides (e.g., methoxychlor) have estrogenic activities that can
initiate inappropriate physiological responses in estrogenic-sensitive tissues following
exposure in vivo. Thus, the current study was designed to determine whether the
VEGFR-2-luciferase (Luc) reporter transgenic mouse is a useful model for evaluating
estrogenic tendencies of methoxychlor (MXC) by monitoring rate of wound healing via
VEGFR-2-mediated gene expression using bioluminescence and real-time imaging
technology. VEGFR-2-Luc male mice were assigned to one of four treatments
(n=8/group); safflower oil alone, 0.05 mg/kg/d estradiol-17β (E2), 30 or 150 mg/kg/d
MXC administered by oral gavage for 14d. On d 0, two sets of full thickness wounds (6
mm punch) were generated under anesthesia on the dorsal aspect of the mice. Photonic
emission images were recorded from wound sites following luciferin injection (150mg/kg
i.p.) on d 0, and d 2, 4, 7, 9, 11, and 14 post wounding to quantify luciferase activity
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using a IVIS 100 imaging system. VEGFR-2-Luc gene activity peaked by d 7 (P<0.001)
in all groups but was not different (P>0.05) between groups. MXC or E2 did not alter
VEGFR-2-Luc mediated gene expression suggesting that the VEGFR-2-Luc transgenic
mouse wound model may not be optimal for monitoring estrogenic compounds.
Introduction
Wound healing is an organized response to organ or tissue injury, or part of the
normal tissue repair and turnover process that is observed for example, in the female
reproductive system. This process is characterized by a complex and diverse set of
cellular activities that include acute and chronic inflammation, cell migration,
angiogenesis, and matrix deposition [1]. Wound healing models are useful tools for
understanding tissue repair and regeneration processes such as angiogenesis, and the
cellular activities associated therein. Angiogenesis, the formation of capillary sprouts
from preexisting blood vessels, is vital to many physiological and pathological processes
including cycling of the female reproductive tract, wound healing, and tumor formation.
Each of these processes depends on the formation of new blood vessels to deliver oxygen
and other required nutrients to newly formed or growing tissues. This neovascularization
is highly regulated by vascular endothelial growth factor (VEGF), a specific mitogen for
vascular endothelial cells [2]
VEGF elicits physiological responses by binding to one of several membrane
bound tyrosine kinase receptors including VEGF receptor-1 (VEGFR-1), VEGF receptor2 (VEGFR-2), and VEGF receptor-3 (VEGFR-3). Of these receptors, VEGFR-2 is the
major mitogenic receptor and is necessary for the differentiation and proliferation of
endothelial and hematopoietic cells [3]. Evidence that VEGF can regulate its own
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receptor [4, 5] and synchronized expression profiles of VEGF and VEGFR-2 suggests
that VEGF acts in a paracrine manner with tight control over receptor expression patterns
to regulate local angiogenesis [6, 7]. This relationship of VEGF and its receptor is
important when monitoring angiogenesis in discrete areas, such as wound sites.
Furthermore, VEGF has been shown to be regulated by estrogens and
pharmacological evidence has demonstrated that this regulation is mediated by
transcriptional activation of the estrogen receptor. Moreover, evidence to support a role
for estrogen regulation of VEGF expression was confirmed by the discovery of sequences
for the estrogen response element (ERE) on the VEGF gene that bind the estrogen
receptor ER [8]. Given the importance of estrogen in breast and endometrial cancer, and
the importance of angiogenesis in these diseases, several studies have shown that both
estrogens and anti-estrogens are capable of regulating VEGF expression [9-11]. The
skin, whose primary function is protection, also acts as an endocrine organ. According to
receptor distribution and related actions, estrogens exert direct influences on all elements
of skin [12]. It has been recognized for many years that estrogens stimulate the synthesis
and turnover of collagen in rats [13] and humans [14]. Presence of estrogen receptors in
mouse [15] and human [16] skin further emphasize the susceptibility of skin to estrogens.
Likewise studies have shown VEGF to be influenced by estrogens in dermal cells in vitro
[17, 18].
Several agricultural pesticides (e.g., methoxychlor, permethrin, atrazine) in use
today have potent estrogenic activities that can initiate an inappropriate physiological
response within normal and tumorigenic tissues. In light of this evidence, there is a
concern regarding the endocrine disruptive potential of pesticides that possess
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xenoestrogenic tendencies. Pesticides are used for the control of agricultural and indoor
pests, but their ubiquitous use has led to the contamination of food sources, the work
place, homes and the environment [19-21]. Methoxychlor, an organochlorine insecticide,
is frequently used as a replacement for the once popular DDT and is approved for use on
edible food crops (fruits, vegetables) as well as on animals (dairy and beef cattle) [22].
Methoxychlor is considered relatively safe for human use based on its low acute toxicity
(rat oral LD50 6,000 mg/kg). However, methoxychlor is readily metabolized by the liver
to the estrogenic metabolite, 2, 2-bis (4-hydroxyphenyll)-1, 1, 1-trichloreoethane (HPTE),
and is a very effective competitor of the estrogen receptor [23]. Consequently, female
reproductive development may be affected by methoxychlor with varying degrees of
severity. Neonatal mice treated with methoxychlor were observed to have precocious
vaginal opening, persistent vaginal cornification, increased uterine weight, and epithelial
hypertrophy of the vagina and uterus [24].
At issue is the identification of such compounds in an easy, efficient, and timely
manner. Physiologically relevant models with the purpose of screening compounds with
potential disruptive characteristics are needed to better predict how a given compound
may impact the environment. Here, we employ a transgenic mouse wound model to
assess its ability to detect endocrine disruptive effects of estrogenic and xenoestrogenic
compounds (i.e. methoxychlor). Given the importance of VEGFR-2 in VEGF regulated
pathways, the VEGFR-2-Luciferase (Luc) transgenic mouse [25] is a unique animal
model used to non-invasively monitor VEGFR-2 gene expression, thus indirectly
observing the VEGF system in vivo. Using this mouse as a wound model [26] allows for
angiogenesis to be monitored via the VEGF gene system, which is extensively involved
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in the process of neovascularization [2]. The estrogen-sensitive responsiveness of the
VEGF system during tissue repair suggests that it might be a useful model endocrine
system to evaluate the potentially disruptive tendencies of xenoestrogenic chemicals, in
this case agricultural pesticides.
Materials and Methods
Experimental Design
Thirty-two male 10 to 15 week old FVB/N VEGFR-2-Luc transgenic mice
(Caliper Life Sciences, Alameda, CA) were randomly assigned to one of four treatment
groups (n=8): safflower oil alone (Control), estradiol 17β (E2; 0.05 mg/kg/d) [26],
methoxychlor low dose (MXL; 30 mg/kg/d), and methoxychlor high dose (MXH; 150
mg/kg/d). On day 0, mice were anesthetized with isoflurane (1.5-3.0%), and two sets of
6-mm full-thickness wounds were created on the dorsal aspect of the animal following
clipping and cleaning with Betadine surgical scrub [26]. The full-thickness wounds were
created by placing the animal on its side and taking two through by through skin biopsy
punch of the dermis to create two wound sites simultaneously, creating a total of four
wounds/mouse. Following surgery, each mouse was imaged at time zero on day 0 while
under anesthesia and then returned to the animal room. Animals were housed separately
under controlled temperature (22 °C) and photo-period (12h : 12h light : dark), with
unlimited access to food and water.
Animal Care
Post-surgery recovery was implemented by keeping animals warm (towelwrapped) while not undergoing imaging. Analgesia for the mice was provided by the
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addition of acetaminophen (1.5 mg/ml) to the water for the first seven days of the study.
Mice were maintained on a phytoestrogen-free, casein-based rodent diet (Test Diet 8117;
Purina, Richmond, IN) to minimize the potential of phytoestrogenic influence on
VEGF/VEGFR-2 expression and subsequent wound healing process. This study
followed the NRC (1996) Guide for the Care and Use of Laboratory Animals (2002) and
was approved by the Mississippi State University Institutional and Animal Care and Use
Committee.
Treatment Delivery
Estradiol 17β and methoxychlor were administered daily from day 0 (day of
wounding) in 100 μl of safflower oil by oral gavage at respective treatment group doses
for a 14-day period. Safflower oil was administered alone as the control treatment (100
μl/d for 14 d).
Bioluminescent Imaging
Serial images of photonic emissions were recorded (5-min collection of photons)
from wound sites 10 min after administration of luciferin (150 mg/kg i.p.) following
initial wound induction on day 0 and on days 2, 4, 7, 9, 11, and 14 post wounding [26] to
measure VEGFR-2-Luc reporter driven luciferase activity using an IVIS 100 biophotonic
imaging system (Caliper Life Sciences, Alameda, CA). Luciferase activity (i.e.,
photons/second) was quantified and analyzed using Living Image software (Caliper Life
Sciences, Alameda, CA). Regions of interest (ROIs) where created around individual
wound sites and photonic emission data obtained from the wound ROIs was used to
analyze VEGFR-2-Luc reporter gene activity. During the imaging procedure, animals
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were anesthetized (1.5-3.0% isoflurane) and maintained on a 37˚C heated platform to
ensure stability while photonic emissions were recorded from the wound sites. Percent
change in wound area was also calculated using Living Image software to monitor the
rate of actual wound closure over time.
Dermal Tissue Preparation
Four mice from each group were euthanized on day 7 and the remaining four on
day 14 post-wounding for acquisition of dermal tissue samples. Each mouse had four
punch wounds on the dorsal aspect of the animal. Each of these wounds was excised
along with approximately 5.0 mm of the surrounding tissue. Two tissue samples from
each mouse were fixed in 10% formalin and two tissue samples were snap frozen in
liquid nitrogen for histopathology and molecular analysis respectively.
Molecular Analysis of VEGF mRNA Expression
Determination of murine-specific VEGF mRNA from dermal wounds was
performed and confirmed using reverse transcription-polymerase chain reaction (RTPCR). Total RNA from dermal tissue samples was extracted and purified using Trizol
reagent according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA).
Quantitation and purity of RNA preparations was performed by UV spectrophotometry
with purity determined by measuring the absorbance 260:280 nm ratio and concentration
determined using the Beer-Lambert law. Total RNA from each sample (2.5 μg) was
reverse transcribed into first-strand cDNA using the MuLV reverse transcriptase and
random hexamers provided from the Retroscript kit (Ambion, Austin, TX). The PCR
reaction was performed using the resulting cDNA template and proprietary components
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of the mouse VEGF Relative RT-PCR Kit (Ambion, Austin, TX). Annealing temps and
cycle numbers were obtained from the Ambion Kit’s protocols. Products were resolved
by electrophoresis on a 2% agarose gel. RNA variability was normalized using 18S
RNA, which was amplified in a multiplex reaction along with VEGF. Image J was used
to quantify band intensities associated with VEGF and 18S RNA. For each sample, the
VEGF band intensity was divided by the intensity of the corresponding 18S RNA band.
Data are expressed as VEGF mRNA levels as a percent of 18S RNA.
Detection of ERα in Dermal Tissue
Estrogen Receptor α (ERα) mRNA expression in dermal tissue samples was
detected using the XpressPackTM ERα (human, mouse, rat) mRNA Expression Analysis
Kit and the XpressPackTM Luminescent Detection System (Chemicon International,
Temecula, CA). The company’s specific guidelines and protocols were followed in order
to verify presence of ERα mRNA.
Histology
Sections (5µM) of fixed, paraffin wax-embedded dermal wound samples were
mounted on glass slides. Standard histological protocols for Masson’s Trichrome and
Factor VIII (F8) staining [27] were performed on tissue to evaluate collagen content and
endothelial cell presence respectively.
Statistical Analysis
The experimental design is one of repeated measures (multiple measurements in
time on each mouse) with subsampling (four measurements per mouse per day treatment
combination). The statistical analysis was performed using the PROC MIXED function
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in SAS version 8.02 (SAS, Cary, NC). The animal was the random-effect component,
and effects were considered significant where P < 0.05.
Results and Discussion
Real-Time Bioluminescent Monitoring of VEGFR-2-Luc In Vivo
This study was undertaken to investigate the relevance and value of using
biophotonics and real-time imaging technology as a tool to screen for compounds with
estrogenic activities. In this experiment we test the efficacy of using the VEGFR-2-Luc
transgenic mouse to indirectly monitor VEGF activity via VEGFR-2-Luc gene
expression, in conditions influenced by estrogen or an estrogenic compound (i.e.
methoxychlor). The rationale for using this animal model was based on three main
criteria: 1) the mouse is an established model for wound healing studies in vivo [26], 2)
VEGFR-2 is transcriptionally regulated by VEGF during angiogenesis [4, 5], 3)
biophotonics technology provides an opportunity to monitor, both in real time and
temporally, genes of interest under physiologically relevant experimental conditions.
VEGFR-2 promoter driven gene expression was able to be measured as photonic
emission from wound sites. Representative bioluminescent images of VEGFR-2-Luc
transgenic mice (Fig 3.1) clearly show photonic emission radiating from wound sites.
However, when photonic signal representing VEGFR-2-Luc reporter gene activity was
quantified and analyzed for a treatment by day effect no significant (P > 0.05) difference
was observed (Fig 3.2). Area under the curve (AUC) was analyzed for the presence of an
overall treatment effect and determined not to be significant (P>0.05) between treatment
groups (Fig 3.3). However, since no significant difference was observed between
treatments on any given day, data was pooled for each day and VEGFR-2-Luc-mediated
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gene expression was plotted over time. VEGFR-2-Luc reporter gene activity increased
(P < 0.05) over time with peak values obtained on day 7 post wounding (Fig. 3.4), which
is consistent with results of similar studies [25]. Rate of wound closure is also shown in
Figure 3.4 as percentage of day 0 wound area. All wounds from all animals were
averaged together to create the rate of wound area closure depicted in Figure 3.4. There
was no statistical difference in rate of wound closure between treatment groups.
Although no significant difference in rate of wound closure was noticed between
treatment groups, the profile of wound closure during the experiment provides a good
reference of the wound healing process. It can be seen that as the wound site gets
smaller, i.e. granulation tissue deposition, that the intensity of photonic signal increases.
This is due to the increase in VEGFR-2-Luc production associated with the angiogenesis
required to nourish the newly formed tissue.
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Figure 3.1

VEGFR-2-Luc Reporter Gene Activity

VEGFR-2-Luc mediated gene expression in a mouse wound model. Mice were assigned
to one of four treatment (groups n=8/group): safflower oil alone (Control), estradiol 17β
(50µg/kg/d), methoxychlor low dose (30 mg/kg/d), and methoxychlor high dose (150
mg/kg/d). Luciferase activity (i.e., photons/second) was quantified using Living Image
software. To detect photonic emission, mice were injected with luciferin (150 mg/kg in
phosphate buffered saline i.p.). Ten minutes after luciferin administration, photons from
wound sites were captured for 5 min using the IVIS 100 biophotonic imaging system. A
representative animal from each treatment group is shown on Days 0 to Day 14. The
min/max pseudo color values representing relative light units (RLUs) was normalized
across all animals.
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Figure 3.2

Wound Site Photonic Emission By Treatment

VEGFR-2-Luc-mediated gene expression from dermal wounds expressed as
photons/second. Luciferase activity (i.e., photons/second) was quantified using Living
Image® software. The Day 0 wound image was taken immediately following wound
induction and subsequent images were taken on Days on d 2, 4, 7, 9, 11, and 14 postwounding. Data is shown as mean ± standard error for each treatment group. Values
between treatment groups were not significantly (P>0.05) different
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Figure 3.3

Area Under Curve by Treatment

VEGFR-2-Luc-mediated gene expression from dermal wounds expressed as area under
the curve (AUC) to determine if an overall treatment effect was present. Control
(safflower oil), E2; estradiol 17β (50µg/kg/d), MXC Low; methoxychlor low dose (30
mg/kg/d), and MXC High; methoxychlor high dose (150 mg/kg/d). There was no
significant differences (P>0.05) in AUC between treatment groups.
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Figure 3.4

Photonic Emission and Percent Wound Area

VEGFR-2-Luc mediated gene expression from dermal wounds expressed as
photons/second. Since no significant difference was observed between treatments on any
given day, data was pooled for each day and VEGFR-2-Luc mediated gene expression
plotted over time. The Day 0 wound image was taken immediately following wound
induction and subsequent images were taken on Days 2, 4, 7, 9, 11, and 14 postwounding. Peak values were observed on d7 and were significantly different (P<0.05)
than other measured values. Percent wound closure is shown to show rate of wound area
closure over time relative to VEGFR2-luc-mediated gene expression.
One of the main criteria that the wound healing mouse model used in this study
was based on is the fact that VEGFR-2 is transcriptionally regulated by VEGF during
angiogenesis [4, 5]. Hence, VEGFR-2-Luc reporter activity was utilized as an indirect
measure of VEGF gene expression in these mice. To verify VEGF gene expression in the
wound sites, semi-quantitative RT-PCR was employed on the tissue samples recovered
from days 7 and 14. Endogenous VEGF gene expression in dermal wound tissue was
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confirmed by RT-PCR. No significant differences (P>0.05) in VEGF gene expression
was seen between day 7 and day 14 tissue samples. Therefore, data was pooled across
day and analyzed for an overall treatment effect. Figure 3.5 shows overall relative VEGF
gene expression as a percentage of 18S internal control. Neither dose of MXC had a
significant effect (P>0.05) on relative VEGF gene expression compared to the control
group or to the estradiol (50µg/kg) treated group. However, when compared to the
control group the E2 treatment group significantly (P<0.01) upregulated VEGF mRNA
expression. The fact that E2 upregulated endogenous VEGF, yet failed to have a
significant effect on VEGFR-2-Luc reporter gene activity may suggest that a mouse
wound model utilizing a VEGF-Luc reporter gene may be more applicable for screening
chemicals with estrogenic tendencies.
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Figure 3.5

Relative VEGF mRNA Expression

Relative VEGF gene expression in dermal wounds measured by semi-quantitative RTPCR. The ratio of VEGF mRNA expression to 18S RNA is expressed as a percentage.
Control (safflower oil), E2; estradiol 17β (50µg/kg/d), MXC Low; methoxychlor low
dose (30 mg/kg/d), and MXC High methoxychlor high dose (150 mg/kg/d). Different
superscripts indicate significant differences between treatment groups. Data is presented
as LS-Means ± SEM where differences were considered significant when P<0.05.
ER Alpha Gene Expression in Dermal Tissue
It has been well established that MXC mimics E2 action in vivo and can cause
adverse developmental and reproductive effects in rodents such as: embryo toxicity,
precocious puberty, decreased fertility and ovarian atrophy. Chapin and colleagues [28]
described changes in reproductive, immune and nervous system function in juvenile mice
exposed to methoxychlor. Others have observed specific effects on male reproductive
development in mice due to exposure during fetal life [29]. In a study performed by
Chen et al., [30] several pyrethroid (permethrin, cypermethrin, deltamethrin) pesticides
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were found to induce MCF-7 cell (a breast cancer cell line) proliferation and that this
effect was blocked by ICI 182,780, a potent estrogen receptor antagonist. Moreover,
these same pyrethroid pesticides inhibited the binding of [3H]-estradiol to the estrogen
receptor [30]. Additionally, estrogen-stimulated release of growth factors (e.g.,
transforming growth factor; TGF-α, epidermal growth factor; EGF, and insulin-like
growth factor; IGF-1) can act synergistically with estrogenic compounds to accelerate
cancer cell growth [31] and enhance ER/ERE-mediated transcriptional processes [31-33].
In the case of dermal wound healing it is important to note the importance of
estrogen receptors in dermal tissue. There is ample evidence demonstrating receptor
distribution and related actions to show that estrogens have a direct influence on all
elements of skin [12]. Ashcroft et al. demonstrated that applying estrogen topically to
murine animal models accelerates cutaneous wound healing of acute incisional wounds,
presumably in part due to estrogens pro-angiogenic tendencies [34].
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Figure 3.6

ER α Gene Expression

Estrogen Receptor α (ERα) mRNA expression in dermal tissue samples was detected
using the XpressPackTM ERα (human, mouse, rat) mRNA Expression Analysis Kit and
the XpressPackTM Luminescent Detection System (Chemicon International, Temecula,
CA). Results are expressed as relative light units (RLUs). Each treatment: Control, E2,
methoxychlor low dose (ML), and methoxychlor high dose (MH) is shown with day 7
mean ER expression in white and day 14 mean ER expression in black. No statistical
differences (P>0.05) were measured between treatment or days post wounding.
The methoxychlor metabolite HPTE has been shown to be an estrogen receptor α
(ERα) agonist [35, 36]. In turn, it was postulated that orally exposing these mice to MXC
and the subsequent production of HPTE that photonic emission from wound sites would
be effected due to ERα presence in dermal tissue. The presence of ERα in dermal tissue
was confirmed by mRNA expression. No significant differences (P > 0.05) between
treatment or days post wounding were noted (Fig 3.6). However, the confirmation of
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ERα mRNA expression verifies the presence of an essential component of the pathway
involved in estrogen signaling affecting VEGF/VEGFR-2 expression.
Histological Analysis
It has long been recognized that estrogens stimulate the synthesis and turnover of
collagen in animal skin [12, 37, 38]. Hence, in this experiment collagen deposition was
analyzed by trichrome staining of histological samples of wound tissue. Histological
analysis was performed on each wound sample from each animal. All samples showed
ample collagen content in wound sites indicated by the blue tissue of samples A-D in (Fig
3.7 A-D). However no observable difference in collagen deposition was noted between
treatments or days post wounding in analyzed wound tissue samples. Endothelial cells
that are involved in the angiogenic process are the main source of VEGF and VEGFR-2
and make up the vascular networks immured in the newly formed tissues of the healing
wounds. Endothelial cell composition was analyzed via endothelial cell stain F-8.
Evidence of vascular cell deposition was evident in samples E-H in (Fig. 3.7 E-H)
indicated by the brown colored areas, yet no differences were observed in vascular cell
deposition between treatments or days post wounding in analyzed wound samples.

76

Figure 3.7

Histological Analysis of Day 7 Wound Samples

Histological samples of Day 7 wound tissue at 40X magnification. A-D represent
samples stained with Tri-Chrome. [A] Wound tissue from a representative control
animal, [B] E2 (50µg/kg/d), [C] Methoxychlor low dose (30mg/kg/d), [D] Methoxychlor
high dose (150mg/kg/d). Collagen is stained blue in the samples. There were no noted
differences in collagen content between treatment groups. E-H represent samples stained
with F-8. [E] Control, [F] E2, [G] Methoxychlor low dose (30mg/kg/d), [H]
Methoxychlor high dose (150mg/kg/d). Vascular cells are stained brown in the samples.
There was no noted difference in vascular cell staining between treatment groups.
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Conclusions
This study was undertaken to investigate the relevance and value of using
biophotonics and real-time imaging technology as a tool to screen for compounds with
estrogenic activities. Monitoring compounds with estrogenic activity with the transgenic
mouse wound model applied in this study proved to be insufficient in terms of significant
differences of VEGFR-2-Luc reporter gene activity between treatment groups. This
could have arisen from any number of reasons including the fact that this model
employed monitoring estrogen’s effect on VEGF indirectly through VEGFR-2. Although
VEGF transcriptionally regulates VEGFR-2 during angiogenesis [4, 5], monitoring
VEGF directly may provide a more acute method of monitoring angiogenesis. A more
relevant model capable of monitoring VEGF directly, would employ a transgenic VEGFLuc mouse, which was not made available at the time these studies were undertaken. It is
also important to note that although MXC is an estrogenic compound it is considered a
weak estrogen [39], and the concentrations used in this study may have been too low to
elicit an estrogenic response. Another possibility that gives rise to the marked error in the
averages between treatment groups is the variability of luciferase driven light activity
between individual animals. This variability possibly comes from the way in which these
transgenic animals are produced. These VEGFR-2-Luc mice were produced through the
process of microinjecting a transgene into the pronuclei of one celled embryos. This
method has many positive attributes, however a main drawback is that microinjection
leads to random integration of the transgene into the recipient’s genome. This results in a
mosaic animal in which not all cells of the animal contain the transgene or same number
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of copies of the transgene, leading to high variability in transgene expression between
individual animals [40].
The need for relevant and accurate physiological models for monitoring hormone
mimicking compounds is a major concern of modern science. The physiological model
employed in this study did not produce precise enough results to decisively verify its use
as a tool in this manner. However, this particular line of transgenic mouse is a useful tool
to monitor angiogenesis via a VEGFR-2-Luc reporter system in a wound healing
environment.
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CHAPTER IV
PHOTONIC MONITORING OF VASCULAR ENDOTHELIAL GROWTH FACTOR
RECEPTOR 2 GENE EXPRESSION IN REAL TIME UNDER RELAXIN-INDUCED
CONDITIONS IN A NOVEL MURINE WOUND MODEL

Abstract
Relaxin is known to promote vascular endotheilial growth factor (VEGF)
expression in reproductive tissue and successful wound-healing is dependent upon good
vascularization of wound sites, a process that relaxin may facilitate. Thus, the objective
of this study was to evaluate the efficacy of relaxin on development of vascular tissue at
wound sites in a novel VEGF receptor-2-Luc (VEGFR-2-Luc) transgenic mouse wound
model by monitoring rate of VEGFR-2-Luc-mediated gene expression using
bioluminescence and real time imaging. To this end, 12 FVB/N VEGFR-2-Luc transgenic
male mice were assigned to treatments (6/group); saline alone or relaxin (1μg/6hr/14 d)
administered i.p. On d 0, a set of full-thickness wounds (6 mm punch) were generated
under anesthesia on the dorsal aspect of each mouse. Photonic emissions were recorded
(5 min collection of photons) from wound sites 10 min after administration of luciferin
(150 mg/kg i.p.) on d 0, and d 1, 2, 4, 7, 9, 11, and 14 post-wounding to quantify
luciferase activity using an IVIS 100TM biophotonic imaging system. Animals were
sacrificed (3/group) on d 7 and 14, and wound tissue specimens recovered for molecular
and histological analyses. While photonic emission from wound sites increased
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(P<0.001) over time with peak values obtained on d 7, there was no significant (P>0.05)
effect of relaxin treatment on VEGFR-2-Luc gene expression at wound sites. Whereas
measuring relaxin’s effect on angiogenesis via the VEGFR-2-Luc wound model was not
accomplished, photonic imaging provides an exciting new tool using alternative models
(i.e., VEGF-Luc mouse) to study relaxin-induced gene expression in normal or
tumorigenic tissues in real-time.
Introduction
Approximately 6.5 million patients are affected by chronic wounds in the United
States. It is estimated that over $25 billion US dollars is spent annually on the treatment
of chronic wounds. With the rapidly growing cost of health care associated with an aging
population and an increase in obesity, the cost of wound treatment will continue to grow
[1]. Thus, wound managment is a major concern of the health care system and a key
challenge to pharmaceutical companies to provide a new generation of wound healing
products.
The development of biological wound products has seen a prodigious amount of
growth as the physiology of wound healing has become more transparent. Wound
healing is an organized response to organ or tissue injury, or part of the normal tissue
repair and turnover process that is observed for example, in the female reproductive
system. This process is characterized by a complex and diverse set of cellular activities
that include acute and chronic inflammation, cell migration, angiogenesis, and matrix
deposition [2]. The development of biological wound healing products aims at
augmenting these cellular activities that are associated with wound healing [3].
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Angiogenesis, the formation of capillary sprouts from preexisting blood vessels, is
a vital part of the wound healing process. This neovascularization is highly regulated by
vascular endothelial growth factor (VEGF), a specific mitogen for vascular endothelial
cells [4]. VEGF elicits physiological responses by binding to one of several membrane
bound tyrosine kinase receptors including VEGF receptor-1 (VEGFR-1), VEGF receptor2 (VEGFR-2), and VEGF receptor-3 (VEGFR-3). Of these receptors, VEGFR-2 is the
major mitogenic receptor and is necessary for the differentiation and proliferation of
endothelial and hematopoietic cells [5]. Evidence that VEGF can regulate its own
receptor [6, 7], and synchronized expression profiles of VEGF and VEGFR-2 suggests
that VEGF acts in a paracrine manner with tight control over receptor expression patterns
to regulate local angiogenesis [8, 9]. This relationship of VEGF and its receptor is
important when monitoring angiogenesis in discrete areas, such as wound sites.
There is a growing interest in the insulin like family of peptide hormones, namely
the insulin-like growth factors (IGFs), relaxin, and relaxin-like peptides. Being naturally
involved in tissue repair and remodeling in the adult, these hormones may have the
potential to expedite the wound healing process by facilitating angiogenesis. These
peptide hormones are known to be important in tissue remodeling of reproductive tissue
(ovary, uterus and cervix) [10-14]. Moreover, recent studies have shown a direct role of
relaxin on the induction of IGFs [15] and VEGF expression in reproductive tissues [1618], and the growth and development of blood vessels at tissue sites other than
reproductive tissue [19, 20].
Researchers have demonstrated relaxin’s ability to induce both fibroblast growth
factor (FGF) and VEGF in THP-1 cells, a cell line of monocyte lineage, in vitro and in
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ischemic wounds in vivo [19] and to significantly increase rate of granulation and closure
[20]. Interestingly, there is evidence to suggest that the effects of relaxin on reproductive
tissue may be estrogen receptor dependent [21, 22] or at least involve cross talk between
relaxin receptors 1 and 2 (RXFP1/RXFP2) and the estrogen receptor complex [23].
Moreovoer, a number of studies have highlighted the potential therapeutic role of relaxin
as a pharmalogical agent [24]. Relaxin may be beneficial when applied at time of wound
dressing or incorporated into wound dressings and released at the site of healing to
facilitate growth and development of blood vessels and new tissue. In the study
conducted by Unemori et al., the ability of relaxin to induce angiogenesis was tested
using the murine Matrigel system [19]. Unemori et al. found that the Matrigel/relaxin
mixture induced significantly more vessel ingrowth than vehicle alone. This study also
showed upregulation of VEGF mRNA in response to relaxin administration in vivo using
Hunt-Schilling wound chambers implanted in rats and in vitro using the macrophage cell
line, THP-1 [19].
Conversly, relaxin is reported to increase breast tumor growth [25-27] and
differentiation and to promote invasiveness of breast cancer cells [28, 29] presumably
because of its pro-angiogenic properties. Relaxin’s affect on angiogenesis makes it an
ideal biological candidate for a wound healing agent.
In the current study, we used the VEGFR-2-Luciferase (Luc) transgenic mouse as
a novel murine wound model to investigate and evaluate the angiogenic potential of
relaxin. Given the importance of VEGFR-2 in VEGF regulated pathways, the VEGFR-2Luc transgenic mouse is a unique animal model used to non-invasively monitor VEGFR2 gene expression, thus indirectly observing the VEGF system in vivo. Hence, when the
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VEGFR-2 gene is activated by a hormone or compound ( i.e., wound healing drug,
angiogenic factor, relaxin), transcription can be measured by bioluminescence
(biophotonics) imaging in real time using the IVIS 100TM Imaging System (Caliper Life
Sciences, Alameda, CA).
Materials and Methods
Experimental Design
This study was designed to determine whether the VEGFR-2-Luc reporter
transgenic mouse is a useful model to evaluate the angiogenic potentiating capabilities of
relaxin by monitoring rate of wound-healing via VEGFR-2-Luc-mediated gene
expression using bioluminescence and real time imaging. To this end, mature male
FVB/N VEGFR-2-Luc trangenic mice purcahsed from Caliper Life Sciences, (Alameda,
CA), through Taconic (Germantown, NY), were assigned to one of two treatment groups:
a) saline control (n = 6), or b) relaxin-treated (n = 6).
On day, 0 mice were anesthethized with isoflurane (1.5% to 3.0%) and a set of six
mm full thickness wounds were created on the dorsal aspect of the animal following
clipping and cleaning with surgical scrub (betadine). Full thickness wounds were created
using an augmented protocol [30] whereby the dorsal aspect of the dermis was tented
perpendicular to the body and a single through by through 6mm punch biopsy was
performed creating to wounds simutaneously parrallel to the midline of the back.
Following surgery, each mouse was immediatly imaged on Day 0 while under anesthesia
and returned to the animal room. Animals were housed separately under controlled
temperature (22 °C) and photo-period (12h : 12h light : dark), with unlimited access to
food and water.
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Animal Care
Comfort and recovery of animals from anesthesia was facilitated by keeping
animals warm (towel-wrapped) while not undergoing imaging. Pain management was
performed by the addition of Acetaminophen (1.5 mg/ml) to the water for the first seven
days of the study. Mice were maintained on a phytoestrogen-free, casein based rodent
diet, (Test Diet 8117, Purina, Richmond, IN) to reduce the potential estrogenic influence
on VEGF/VEGFR-2 gene expression and the wound healing process. This study followed
the NRC (1996) Guide for the Care and Use of Laboratory Animals (2002) and was
approved by the Mississippi State University Instituitonal and Animal Care and Use
Committee.
Hormone Delivery
Purified porcine relaxin (CM-A fraction; 3000 U/mg) was prepared by extraction
and purification from ovaries of pregnant sows [31]. Purity was confirmed by SDSPAGE, which revealed a single band of approximately 6.2 kDA. The biological activity
of the relaxin preparation was ascertained by inhibition of spontaneous uterine mobility
in vitro [32], and immunoreactivity was verified by RIA [33]. Relaxin was re-suspended
in sterile phosphate buffered saline and administered by intra peritoneal injection (i.p.) in
100 µl aliquots of 1 µg every 6 hours over a 14 day period (1 μg in 100 ml saline/6hr/14
d). Saline was administered without relaxin as the control treatment (100 µl/6h/14 days).
Treatment delivery commenced immediately following Day 0 imaging.
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Bioluminescence Imaging
Serial imaging of photonic emissions were recorded (5 min collection of photons)
from wound sites 10 min after administration of luciferin (150 mg/kg in 150 µl saline
i.p.) following initial wound induction on Day 0, and on Days 1, 2, 4, 7, 9, 11, and 14
post-wounding [34, 35] to measure luciferase activity using an IVIS 100TM biophotonic
imaging system (Caliper Life Sciences, Alameda, CA). Luciferase activity (i.e.,
photons/second) was quantified and analyzed using Living Image® software [35].
During the imaging procedure, animals were anesthetized (1.5% to 3.0% isoflurane) and
maintained on a 37°C heated platform to ensure stability while photonic emissions were
being recorded from the wound sites.
Dermal Tissue Preparation
Three mice from each group were euthanized on day 7 and the remaining 3 on
day 14 post-wounding for acquisition of dermal tissue samples. Each mouse had 2 punch
wounds on the dorsal aspect of the animal. Each of these wounds was excised along with
approximately 5.0 mm of the surrounding tissue. One tissue sample from each mouse
was fixed in 10% formalin and one tissue sample were snap frozen in liquid nitrogen for
histopathology and molecular analysis respectively.
Molecular Analysis of VEGFR-2 mRNA Expression
Determination of murine-specific VEGFR-2 mRNA from dermal wounds was
performed and confirmed using RT-PCR. Total RNA from dermal tissue samples were
extracted and purified using TRIZOL® Reagent according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). Quantitation and purity of RNA preparations
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was performed by UV spectrophotometry with purity determined by absorbance 260/280
nm ratio and concentration determined using the Beer-Lambert law. Total RNA from
each sample (2.5μg) was reverse transcribed into first-strand cDNA using the MuLV
reverse transcriptase and random hexamers provided for by the RetroscriptTM kit from
(Ambion, Austin, TX). PCR was performed by using the resulting cDNA template, along
with the forward and reverse primers:
5’-CAGATGGACGAGAAAACAGTAGAGGCGTTGGC-3’ and
5’GAGGACTCAGGGCAGAAAGAGAGCG-3’ respectively. The thermocycler (Master
Cycler – Gradient, Eppendorf Scientific, Westbury, NY) was programmed for: 94˚C for 5
min, 30 cycles of 94˚C for 45 sec, 60.7˚C for 45 sec, 72˚C for 45 sec, and 72˚C for 2 min.
SuperTaq polymerase and buffers (Ambion, Austin, TX) were used to carry out the PCR
reactions. Products were resolved on a 2% agarose gel electrophoresis and yielded a 583
bp product consistent with VEGFR-2.
RNA variability was normalized using 18S RNA as an internal standard. Relative
quantitative PCR was performed by amplifying 18S RNA in a multiplex reaction along
with the VEGFR-2 primers using Quantum RNA 18S internal standards and competimers
(Ambion, Austin, TX).
Statistical Analysis
The experimental design is that of a repeated measures design (multiple
measurements in time on each mouse) with subsampling (two measurements per mouse
per day-treatment combination). Wound site photonic emission for each animal was
normalized by Day 0 wound values. The statistical analysis was performed using PROC
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MIXED in SAS 8.02 (SAS, Cary, NC). The animal was the random effect component
and significance was set at P<0.05.
Results and Discussion
Real-Time Bioluminescent Monitoring of VEGFR-2 In-Vivo
These studies were undertaken to investigate the relevance and value of using
biophotonics and real time imaging technology as a tool to evaluate the role of relaxin in
the wound-healing process in vivo. In this experiment we attempted to determine VEGF
activity indirectly during wound healing under relaxin experimental conditions by
measuring VEGFR-2 gene expression using the VEGFR-2-Luc transgenic mouse. The
rationale for using this animal model was based on three main factors: 1) the mouse is an
established model for wound-healing studies in vivo [30], 2) the VEGFR-2 is
transcriptionally regulated by VEGF during angiogenesis [7], and 3) biophotonics
technology provides an opportunity to monitor in real time and temporally genes of
interest under physiologically relevant experimental conditions.
VEGFR-2-Luc reporter gene expression, measured as photonic emission from
wound sites (Fig 4.1) showed no significant (P > 0.05) effect of relaxin treatment on
VEGFR-2-Luc reporter gene expression at wound sites (Fig 4.2). Since no significant
difference was observed between treatments on any given day, data was pooled for each
day and VEGFR-2-Luc-mediated gene expression was plotted over time. VEGFR-2-Luc
reporter gene expression increased (P < 0.001) over time with peak values obtained by
day 7 post wounding (Fig 4.3) followed by a decrease in photonic signal on
corresponding imaging days.
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Figure 4.1

VEGFR-2-Luc-Mediated Gene Expression

VEGFR-2-Luc reporter gene expression from VEGFR-2-Luc mouse dermal wounds
expressed as photons/second shown in pseudo-color. Mice were assigned to one of two
treatment (groups n=6/group): saline control or relaxin treated. Luciferase activity (i.e.,
photons/second) was quantified using Living Image® software. Two representative
animals from each treatment group are shown in the above image. The Day 0 wound
image was taken immediately following wound induction and subsequent images were
taken on Days on d 1, 2, 4, 7, 9, 11, and 14 post-wounding.
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Figure 4.2

VEGFR-2 Luc Reporter Gene Activity Between Treatments

VEGFR-2-Luc reporter gene expression from dermal wounds expressed as
photons/second. No significant effect (P > 0.05) of relaxin on VEGFR-2-Luc reporter
gene expression was demonstrated. Data is shown as mean photonic emission ± standard
error.
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Figure 4.3

VEGFR-2-Luc Reporter Gene Activity Across Treatments

VEGFR-2-Luc reporter gene expression from dermal wounds expressed as
photons/second. Data represents pooled photonic emission for each day. Photonic
emission significantly (P<0.05) increased over time with peak values obtained on day 7
followed by a decrease in photonic signal. Data is shown as mean photonic emission ±
standard error. Superscript * indicates peak photonic emission.
While VEGFR-2-Luc mediated gene expression was detected in this wound
model and peaked on day 7, which is consistent with previous reports [35], a significant
effect of relaxin treatment was not observed. This could have arisen from any number of
reasons including the fact that this model monitored relaxin’s effect on VEGF indirectly
through VEGFR-2. A more relevant model may employ a transgenic VEGF-Luc mouse,
which was not made available at the time these studies were undertaken. Another
possibility that gives rise to the marked error in the averages between treatment groups is
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the variability of luciferase driven light activity between individual animals. This
variability may come from the way in which these transgenic animals are produced.
These VEGFR-2-Luc mice were produced through the process of microinjecting a
transgene into the pronuclei of one celled embryos. This method has many positive
attributes, however a main drawback is that microinjection leads to random integration of
the transgene into the recipient’s genome. This results in a mosaic animal in which not
all cells of the animal contain the transgene or same number of copies of the transgene,
leading to high variability in transgene expression between individual animals [36].
Molecular Analysis of VEGFR-2 mRNA Expression

Figure 4.4

VEGFR-2 mRNA Expression

Confirmation of VEGFR-2 gene expression in tissue specimens from wound sites. A
representative agarose gel shows VEGFR-2 transcript expression as determined by RTPCR from representative tissue samples. Samples from both treatment groups from Day 7
and Day 14 are represented. Gene expression was corrected against 18S mRNA and
shows that relaxin treatment marginally increased VEGFR2 gene expression. Data is
expressed as a ratio of VEGFR-2 mRNA:18S mRNA levels in arbitrary units.
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VEGFR-2 gene expression was confirmed by RT-PCR in wound tissue specimens
recovered on Day 7 and 14 post-wounding (Fig 4.4). This confirms that the VEGFR-2Luc reporter gene is in fact representing an endogenous gene present at the site in which
this wound model measures VEGFR-2 gene activity. Secondly, the representative gel
shown in Figure 4 shows a marginal increase of VEGFR-2 gene expression as measured
by semi quantitative reverse transcription PCR, however this did not translate into
significant differences. Interestingly, this lack of effect of relaxin was also observed of
VEGFR-2-Luc reporter gene activity (Fig 4.2), meaning that endogenous VEGFR-2 and
the VEGFR-2-Luc reporter behave in the same manner in this wound model verifying the
functionality of the wound model for measuring VEGFR-2 activity.
Testicular Expression of VEGFR-2-Luc Reporter Gene Activity
An interesting serendipitous observation in the course of these studies was the
high expression of VEGFR-2 in the testes of VEGFR-2-Luc mice (Fig 4.5). This is not
surprising since the testis is a highly vascularized and dynamic tissue and easily imaged
due to its unique anatomical location. Intriguingly the relaxin treated mice showed an
overall higher level of testicular VEGFR-2-Luc gene activity (P<0.05) (Fig 4.6). This
observation is possibly due to the fact that relaxin receptors RXFP-1 and RXFP-2 are
expressed in abundance in the testis [37, 38]. Moreover, this ligand-receptor complex
plays an important role in normal testicular decent and disruption of this process is
associated with an increased incidence of cryptorchidism [39, 40].

97

Figure 4.5

VEGFR-2-Luc-Mediated Gene Expression in Mice Testes

VEGFR-2-Luc reporter mediated gene expression from mice testes expressed as
photons/second shown in pseudo-color. Red indicates higher levels of VEGFR-2-Luc
reporter gene expression.
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Figure 4.6

Mean VEGFR-2-Luc Gene Expression In Testes

VEGFR-2-Luc reporter mediated gene expression from mice testes expressed as
photons/second. Relaxin treated mice showed an overall increase of photonic emission
from testes (P<0.05).
Conclusions
This model was based on the VEGFR-2-Luc reporter gene being able to measure
relaxin’s effect on the wound healing process. Although relaxin has been shown to affect
the wound healing process, this model was not able to measure the hormone’s effect on
the process; at least as far as the VEGFR-2-Luc reporter gene is concerned. This does not
however disqualify this model for being used for monitoring the wound healing process,
because it was shown to be uniquely suited for temporal in vivo imaging of gene
expression associated with wound healing.
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This mouse clearly has potential for measuring biological compounds effect on
angiogenesis in other type models, i.e. testicular angiogenesis. In fact, the preliminary
data demonstrated here, indicates the testicular model may be useful for monitoring
relaxin’s effect on angiogenesis.
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CHAPTER V
OPTIMIZATION AND FUNCTIONALITY OF A CELL BASED VEGF
BIOPHOTONIC ASSAY

Abstract
PC-3M-Luc cells are stably transfected with a hVEGF-Luc reporter gene
providing a convenient light based response to proangiogenic molecules. A cell based
biophotonic assay was developed using these cells and optimized to accurately measure
VEGF activity in response to angiogenic stimuli. Cobalt chloride (CoCl2), a known
VEGF transcription up- regulator, was used for optimization and the catecholamines E
and NE were used to demonstrate the validity of the assay. Peak signal difference
(P<0.05) between 0µM and 100µM CoCl2 was found to be associated with a cell density
of ~40,000 cell/well. This optimized cell density was then used to demonstrate that E
and NE directly affect VEGF activity in this prostate cancer cell line. Both E and NE
significantly (P<0.05) stimulated VEGF-Luc reporter activity. This assay used in the
manner described in this paper has the potential to discover and unlock other angiogenic
phenomenon associated with a broad range of biological molecules and chemicals
Introduction
Researchers in both industry and academic settings have increasingly become
more dependent on high throughput methods of obtaining data. Information from these
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methods assist in identifying targets that potentially will lead to drug discovery, therapy
development, or answers to basic biological questions. Biochemical target based assays
have been an essential tool in the pharmaceutical industry for years as a method of
measuring processes such as enzymatic activity by purifying specific components of the
reaction. However, not all targets can be purified or prepared in a way that is suitable for
biochemical measurement [1]. Cell based assays offer a more physiological oriented
approach of looking at specific cellular processes. Conventional cell based methods
utilize 6, 12, or 24 well plates to grow and assess cells in experimental environments.
While conventional methods are necessary and functional there is a rationale for further
miniaturization and streamlining cell culture based experiments [2] which has created a
trend towards cell assay miniaturization [3] in the form of 96 well plate cell culture.
Obviously, 96 well plates offer a routine manner of miniaturizing cell culture assays in
any modern lab. Aside from higher throughput, a key advantage of using 96 well plates
over larger plates is the inherent cost reduction due to smaller volumes required for
medias, buffers, reagents, etc [4].
Ninety-six well plate cell culture systems which utilize techniques such as
reporter genes have an implicit capability of testing compounds on cellular processes at a
transcriptional level. Genetic reporter systems are invaluable tools in scientific research
and drug discovery. Many applications both, in vivo and in vitro, use reporter genes as
indicators of transcriptional activity. Bioluminescent reporters such as luciferase fusion
genes offer methods for rapid and convenient measurement of target gene activity.
Assays based on reporter gene photon emission can be adapted to wide variety of
biological targets and automation methods making them ideal high throughput screening
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tools [5] to help gain insight into such high profile research arenas such as cancer
research.
Prostate cancer is the second leading cause of cancer deaths in men behind lung
cancer and remains a public health concern [6]. It is estimated that one in six men will be
diagnosed with the disease during a lifetime and approximately 30,000 men will die from
the disease annually [7]. Currently, hormone therapy is the leading treatment for men
who have androgen-responsive metastatic disease. Hormonal treatments, however,
usually cannot prevent castration resistant prostate cancer (CRPC) from eventually
ensuing [8]. Therefore, there is an area of unmet medical need for new avenues of
prostate cancer treatments and therapies.
Much attention has been paid to the mechanisms involved with the angiogenic
process of cancer formation and progression. Angiogenesis is an integral aspect of
cancer progression and tumor survival [9]. Physiological factors affecting angiogenesis
in turn have the potential to influence solid tumor growth including psychophysiological
factors such as stress. Stress induced catecholamine activity via the hormones
epinephrine (E) and norepinephrine (NE) has been shown to affect vascular endothelial
growth factor (VEGF), the main mediator of angiogenesis, in cancer cell lines [10-12].
Thus, the objective of this study is to develop an optimized protocol utilizing a
cell based 96 well assay to measure VEGF-Luc gene transcription using a stably
transfected prostate cancer cell line. We then access the functionality of the optimized
assay to measure VEGF-Luc mRNA’s response to the catecholamines NE and E.
Hereby, potentially gaining insight into the psychophysiological aspects of prostate
cancer system.
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Materials and Methods
Experimental Design and Rationale
Assay optimization experiments were performed by treating cells with 100 µM
CoCl2 (Sigma-Aldrich, St. Louis, MO, USA) or media alone. CoCl2 is known to
upregulate VEGF gene expression as it chemically induces a hypoxic response in cells
[13]. Optimization experiments include cell number optimization, cell proliferation
analysis, and reporter gene functionality analysis. Following assay optimization
experiments, assay functionality was assessed by testing the effects of the catecholamines
E and NE on VEGF-Luc mRNA activity in a PC-3M-Luc cell line (Caliper Life Sciences,
Alameda, CA, USA). Upregulation of VEGF-Luc mRNA due to CoCl2 treatment was
used as an assay positive control. Functionality experiments were performed using E and
NE (Sigma-Aldrich, St. Louis, MO, USA) to test the stress induced response of hVEGFLuc reporter gene activity. These experiments include a dose and time response analysis
and an adrenal receptor blockade analysis of hVEGF-Luc reporter activity. It should be
noted that serum starvation was not performed in any of the experiments due to the
potential confounding effects of serum starvation on VEGF regulation [14].
Cell Culture
These experiments were performed using PC-3M-Luc cells from Caliper Life
Sciences (Alameda, CA, USA). Cells were maintained and propagated in vitro by serial
passage in phenol red free MEM (Life Technologies, Grand Island, NY, USA )
supplemented with 10% fetal bovine serum (Life Technologies, Grand Island, NY, USA),
1% 100X Non-essential amino acids (Life Technologies, Grand Island, NY, USA ) , 1%
200mM 100X L-Glutamate(Life Technologies, Grand Island, NY, USA ) , 1% 100mM
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Na Pyruvate (Life Technologies, Grand Island, NY, USA ), 1% MEM vitamin solution
(Life Technologies, Grand Island, NY, USA ) , and 1% Penn/Strep(Life Technologies,
Grand Island, NY, USA ) . Cell cultures were replenished after 8-10 passages from
stocks frozen in liquid nitrogen.
Bioluminescent Imaging
Bioluminescent imaging analysis was assessed after cells had been exposed to
respective treatments. Firstly, cell growth media was removed and firefly luciferase
substrate D-luciferin (Caliper Life Sciences, Alameda, CA, USA) was added at a final
concentration of 0.1mM [15]. Cells were then immediately imaged using the cooled
charged coupled device (CCD) camera of the Xenogen IVIS 100 (Caliper Life Sciences,
Alameda, CA, USA). Each plate was imaged for 2 min at stage C with small binning.
Quantification of cellular photonic emission was performed using the Living Image
acquisition and analysis software (Caliper Life Sciences, Alameda, CA, USA).
Assay Optimization Experiments
Cell Number Optimization
To determine the optimum number of cells to seed per well of black clear bottom
96 well plates serial (1:2) dilutions ranging from 5x10 5 cells (column 1) to 300 cells
(column 12) were plated in growth media in each respective column of 96 well plates.
Cells were allowed to attach to well bottoms for a period of 24 h. Wells were then
treated with either 0μM CoCl2 or 100μM CoCl2 , where rows A,C,E,G were treated with
0µM CoCl2 and rows B,D,F,H treated with 100μM CoCl2. 24 h post treatment photonic
emission was assessed using the IVIS 100 system.
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Cell Proliferation Assays
PC-3M-Luc cells were seeded in black clear bottom 96 well plates with 40,000
cells per well (determined by optimization study) in growth media for a period of 24 h in
which they were allowed to securely adhere to well bottoms. After 24 h, cells were
treated with either 0µM CoCl2 or 100 µM CoCl2 in growth media. At 24 h post treatment
cell proliferation was assessed via cell count and crystal violet. Proliferation assessment
by cell count was performed as follows: Cells were washed in (Hank’s balanced salts
solution (HBSS) from Life Technologies (Grand Island, NY, USA) followed by the
addition of 100µl of 1X Trypsin per well. Once cells were completely detached from
well (~3min), they were transferred into centrifuge tubes containing 1ml of growth
media. Cells were centrifuged for 3min at 1500 RPM and pellets were resuspended in
1ml of fresh growth media. The cell count of each tube representing a single well was
assessed using a Countess® automated cell counter (Life Technologies, Grand Island,
NY, USA) as per manufacturer’s instructions. Proliferation assessment by crystal violet
was performed by the method previously described by Kueng et al. [16]. Cells were
washed in HBSS and fixed in 3% glutaraldehyde for 15 min. Fixed cells were then
washed three times by submersion in deionized water and allowed to air dry. Cells were
then stained with crystal violet (0.1% in 20% methanol) for 20 min, followed by three
washes with deionized water. Glacial acetic acid (10%) was then used to elute the crystal
violet and optical density of each well was measured at 590nm.
Reporter Gene Functionality
Functionality of the hVEGF-Luc reporter gene was assessed by seeding PC-3MLuc cells at 40,000 cells/well in black clear bottom 96 well plates. Cells were cultured in
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growth media for 24 h for proficient adherence to well bottoms. After 24 h, cells were
treated with either 0µM CoCl2 or 100 µM CoCl2 in growth media. At 24 h post treatment
reporter gene transcription and translation functionality was assessed by either
quantitative RT-PCR or In-Cell ELISA respectively.
Assay Functionality
Adrenal Hormone Dose/Time Response Analysis
PC-3M-Luc cells were seeded (40,000/well) in black clear bottomed 96 well
plates. After 24 h cells were treated with 0, 0.1, 1, and 10µM E or NE. Cells were
assessed for hVEGF-Luc reporter activity via bioluminescent imaging at 6, 12, and 24 h
post treatment where each time point was represented by a separate 96 well plate.
Adrenergic Receptor Blockade Analysis
PC-3M-Luc cells were seeded (40,000/well) in black clear bottomed 96 well
plates. After 24 h cells were treated with either media alone (control), 100 µM CoCl2
(positive control), 10µM E, 10µM E + 1µM Prazosin (α blocker), 10µM E + 1µM
Propranolol (β blocker) or 10µM NE, 10µM NE + 1µM Prazosin (α blocker), 10µM NE
+ 1µM Propranolol (β blocker). The adrenergic receptor (AR) blockers were applied 1 h
before addition of E or NE [12]. After 24 h of treatment incubation cells were assessed
for hVEGF-Luc activity via biophotonic imaging.
VEGF and HIF-1α in-cell ELISA
PC-3M-Luc cells used in optimization experiments previously analyzed by
bioluminescent imaging were washed twice in HBSS and immediately fixed with 4%
paraformaldehyde. Cytosolic production of VEGF and HIF-1α protein was measured
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using the Pierce Colorimetric In-Cell ELISA kit (Thermo Fisher Scientific Inc, Waltham,
MA, USA) according to manufacturer’s instructions. VEGF and HIF-1α were detected
via colorimetric spectrophotometry and the optical density values were normalized to cell
number using Janus Whole-Cell stain (provided with In-Cell ELISA kit ) according to
manufacturer’s instructions. Primary antibodies for VEGF and HIF-1α used in
conjunction with the In-Cell ELISA kit were purchased from (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA).
RNA extraction and cDNA synthesis
Total RNA from each biological replicate was isolated using the RNeasy Micro
Kit (Qiagen, Valencia, CA, USA) according to the company’s instructions. RNA purity
and concentration were measured using a Nanodrop 1000 (Wilmington, DE, USA) .
Isolated RNA was stored at -20° until reverse transcription was performed. First strand
cDNA synthesis was performed by reverse transcribing previously isolated total RNA
using the QuantiTect® Reverse Transcription Kit (Qiagen, Valencia, CA, USA) as per
manufacturer’s instructions.
Real-Time Quantitative PCR
Primers for RT-PCR were designed (Table 1) from transcript sequences from
GenBank (http://www.ncbi.nlm.nih.gov/genbank) using Primer-BLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast). Primers were synthesized by
(Integrated DNA Technologies, Coralville, IA, USA).
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Table 5.1

Primer Sequences used for Q-PCR

Real-time quantitative PCR was performed using the SYBR green kit from
Qiagen (Valencia, CA, USA) according to manufacturer’s instructions using a
RotorGeneQ Cycler (Qiagen, Valencia, CA, USA) with the following program: 5 min at
95°C; 45 cycles of 5 s at 95°C and 10 s at 60°C and concluded by a melting curve. QPCR products from each primer were pooled by treatment (0 µM or 100 µM CoCl2) and
primer integrity and amplicon efficiency was verified by 2% agarose gel electrophoresis
and melt curve analysis (Fig 5.1).
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Figure 5.1

Primer and Amplicon Verification

Verification of primer integrity and amplicon efficiency. Q-PCR products underwent
electrophoresis on a 2% agarose gel. Specific melt curve peaks (top to bottom)
correspond to the doublets of bands for β-actin, VEGF, and HIF-1α respectively.
Statistical analysis
Experiments were replicated at least three times with at least three replicates for
each treatment within each experiment. Statistical analysis was performed using the SAS
9.3 Statistical Analysis Software (SAS Inst., Inc., Cary, NC ) unless otherwise noted.
The PROC GLM procedure in SAS was used to test for significant difference between
treatments. Results were considered different if P<0.05.
REST 2009 (Qiagen, Valencia, CA) was used to determine relative differences in
gene expression observed in qPCR experiments. This software uses random relocation
and bootstrapping techniques to test for significance between treatment groups and
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controls [17]. REST 2009 uses the formula for testing relative expression levels of genes
compared to a house keeping gene developed by Pfaffl et al [18].
Results and Discussion
Assay Optimization
When performing in vitro cell culture experiments the number of cells to seed into
an experimental sample vessel,(i.e. individual well of 96 well plate) is essential to the
outcome of the experiment. For example, proliferation studies require a cell seeding
density which allows for mitosis and cellular taxis into open space of the growth vessel
surface. In our experiments we were interested in gene activity so proliferation would be
a confounding variable to accurate results. Likewise, this assay’s method of analyzing
gene activity is by measuring photonic emission driven by the promoter region of the
VEGF gene, therefore optimization of the genetic signal (photonic emission) to cell
density was required for a viable cellular assay of this type.
VEGF is highly regulated by hypoxia [19-21] which can be mimicked by CoCl2
[22, 23]. This regulation by hypoxia or CoCl2 is due to stabilization of HIF-1α, which is
the regulatory component of the HIF-1 complex [24] . Thus, CoCl2 was used as a
positive control because it is a known inducer of VEGF mRNA upregulation. Photonic
emission was significantly different between cells treated with 100 µM CoCl2 and cells
treated with 0 µM CoCl2 at cell counts of 75,000 and 37,500 cells/well (P<0.05) (Fig 5.2
A). Differences in bioluminescent intensity can be visualized in Figure 5.2 B where
luminescent intensity is represented by pseudo color. This indicates that the sensitivity
threshold of this assay lies between 75,000 and 37,500 cells/well. Photonic emission
produced from wells with cell counts above 75,000 cells/well lies above the sensitivity
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threshold and cell counts below 37,500 cells/well lies below the sensitivity threshold.
The results of this cell number optimization experiment indicate that significant
differences in photonic signal related to VEGF-Luc reporter activity can be obtained by
seeding wells of 96 well plates with a range of 75,000 to 37,500 PC-3M-Luc cells/well.
A density of 40,000 cells/well was concluded to be the optimum number of cells to seed
per well for this assay. This cell density falls within the sensitivity threshold of the assay
and is closer to the lower end of the range where cell confluency (95%) is at an optimum.
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Figure 5.2

Photonic Emission by Cell Count

(A) Photonic emission by cell count, (B) Pseudo colored representation of photonic
emission per well of PC-3M-Luc cells. (A) Data presented as means ± SEM
(photons/sec). Means within a cell count with an * indicate differences (P<0.05)
between the control group (solid line) and CoCl2 treated group (dashed line). The control
group received 0µM CoCl2 while the treated group received 100µM CoCl2. (B) Data
presented in pseudo color where red indicates higher photonic emission and blue
indicates lower photonic emission. Columns are indicative of cell counts and rows
indicate treatment groups: top (0µM CoCl2), bottom (100µM CoCl2).
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Figure 5.3

CoCl2’s Influence on Cell Proliferation

Cobalt chloride’s influence on cell proliferation at 24 h post treatment measured by (A)
cell count analysis and (B) crystal violet staining method. The white bars represent the
control group (0µM CoCl2) and the black bars represent the treated group (100µM
CoCl2). Data is presented as means ± SEM where (A) is measured in cell count and (B)
is measured in optical density at 590nm. No significant differences (P>0.05) were
observed between treatment groups for either proliferation analysis methodless overall
signal did not demonstrate beginnings of pixel saturation as the high end of 75,000
cells/well did (Fig 1B).
The prostate cancer cell line, PC-3M-Luc, constitutively express the hVEGF-Luc
gene therefore a basal amount of photonic signal is constantly emitted from these cells in
culture. Thus, greater numbers of cells produce higher photonic signals as seen in Figure
5.2. Due to this it was imperative to confirm that CoCl2 does not increase cell
proliferation when cells were seeded at a density of 40,000 cells/well. No significant
differences in cell proliferation were observed when cells were treated with 100µM
CoCl2 for 24 h (Fig 5.3), confirming that differences in photonic signal between treatment
groups can be equated to changes in hVEGF-Luc gene expression.
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Figure 5.4

CoCl2’s Influence on Gene Activity

Cobalt chloride’s influence on hVEGF-Luc reporter gene activity measured by photonic
emission (A). Cobalt chloride’s influence on HIF-1α and VEGF gene activity measured
by qPCR. The white bars represent the control group (0µM CoCl2) and the black bars
represent the treated group (100µM CoCl2). (A) Data is presented as mean ± SEM fold
change compared to control. (B) Data is presented as fold change relative to control
group as calculated by REST 2009. Results were considered statistically significant from
the 0µM CoCl2 treated control if P<0.05 (*).
PC-3M-Luc cells are capable of being utilized in the form of an optimized cellular
assay to monitor the effects of angiogenic compounds on hVEGF-Luc reporter gene
transcriptional activity. However, for this assay to be physiologically accurate
endogenous VEGF mRNA activity has to mimic that of the hVEGF-Luc reporter gene
activity. Interestingly, hVEGF-Luc activity increased 1.43 fold when cells were treated
with 100µM CoCl2 (Fig 5.4 A). Likewise endogenous VEGF gene activity was
increased 1.46 fold when treated with 100µM CoCl2 (Fig 5.4 B). This verifies that
hVEGF-Luc reporter gene activity in PC-3M-Luc cells is physiologically accurate and
can be used to measure VEGF gene activity. In addition to increased gene activity,
VEGF also demonstrated an increase in protein production in response to CoCl2
treatment (Fig 5.5).
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Figure 5.5

CoCl2’s Influence on HIF-1α and VEGF Protein Production

Cobalt chloride’s influence on HIF-1α and VEGF protein activity measured by In-Cell
ELISA. The white bars represent the control group (0µM CoCl2) and the black bars
represent the treated group (100µM CoCl2). Data is presented as mean ± SEM fold
change compared to control. Results were considered statistically significant from the
0µM CoCl2 control if P<0.05 (*).
To substantiate the physiological accuracy of this model, HIF-1α gene activity
was investigated as well. Cobalt chloride did not increase HIF-1α transcription (Fig 5.4
B) yet, HIF-1α protein production was increased (Fig 5.5). As far as oxygen signaling is
concerned this is accurate. Hypoxia or hypoxia mimics (CoCl2) upregulate VEGF
mRNA [13] by the binding of the transcriptional factor HIF-1 to the hypoxia response
element (HRE) on the VEGF promoter [25]. Hypoxia inducible factor-1 is a dimer
consisting of an α and β subunit with the α subunit being the regulatory subunit of the
dimer due to degradation in the presence of oxygen [24, 26]. Under hypoxic or CoCl2
influence HIF-1α is stabilized where it can dimerize with the HIF-1β subunit which is
constitutively expressed. The functional dimer then can carry out its regulatory function
on target genes. Interestingly, HIF-1α and HIF-1β transcription is not affected by oxygen
tension [24]. This is demonstrated here by CoCl2’s influence not affecting HIF-1α
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transcription (Fig 5.4 B) yet increasing the amount of HIF-1α protein production (Fig
5.5).
Assay Functionality
Stress related mediators can stimulate VEGF production in cancer cell lines
including prostate cancer [11, 12]. PC-3M-Luc cells used in this assay were treated with
physiological doses of E and NE [11, 12] which directly stimulated VEGF-Luc reporter
activity (Fig 5.6). Photonic activity (P<0.05) at all three time points (6, 12, and 24 h) was
observed to be highest at the 10 µM dose of both E and NE with 24 h having the greatest
(P<0.05) effect. Therefore, this dose and time point was used in subsequent blocking
experiments. Of interesting note here is the fact that 0.1 µM E and NE increased
(P<0.05) reporter activity at 12 h yet decreased (P<0.05) activity at 24 h. This could
partially be explained by the fact that adrenergic hormones have a relatively rapid course
of action [11, 27]. The relative amount of adrenal hormones available to the cells at the
0.1µM concentration could be initiating the pathway responsible for VEGF gene
induction at 12 h and at 24 h the supply of available hormone for initiating this process is
depleted. The resulting VEGF transcription decrease could be AR related [28] or
possibly a downstream mediator of VEGF expression (HIF-1α) is affected [12].
However, to make conclusions without further investigation would be entirely
speculative. This finding opens up an avenue for future studies concerning VEGF
regulation related to E and NE and AR expression in prostate cancer
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Figure 5.6

hVEGF-Luc Reporter Activity in Catecholamine Treated Cells

Reporter activity (hVEGF-Luc) in PC-3M-Luc cells treated with 0, .1, 1, and 10 µM E
(A), and NE (B). Biophotonic signal via hVEGF-Luc reporter was measured at 6, 12, and
24 h. Data is represented as fold change compared to control (media alone). *, **, and
*** indicate significant differences as compared to control wells at 6, 12, and 24h
respectively. Data is presented as LS-Means ± SEM where differences were considered
significant when P <0.05. Note: stacked significance markers *, **, and *** indicate
significance from controls at concentrations where error bars of respective time intervals
overlap.
This assay was able to demonstrate that the catecholamines E and NE have an
angiogenic effect on PC-3M-Luc prostate cancer cells through the activity of the hVEGFLuc reporter. To verify the effects E and NE had on the hVEGF reporter were
physiological relevant, pharmacological antagonists of adrenergic receptors α and β were
used to observe hormone receptor activity. Cobalt chloride (100µM) was used as an
assay positive control to verify that the assay was working properly.
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Figure 5.7

hVEGF-Luc Reporter Activity Analysis of AR Blockers

Normalized hVEGF-Luc reporter activity in PC-3M-Luc cells treated with 10 µM E (A),
and NE (B) alone for 24h, or pretreated with pharmacological inhibitors of both αARs (1
µM Prazosin) and βARs (1 µM Propranolol) for 1h before treatment with respective
adrenal hormones. Cobalt chloride (100µM) was used as a positive control for
upregulation of hVEGF-Luc reporter activity. Data is represented as fold change
compared to control (media alone). Different superscripts indicate significant differences
between means of respective charts. Data is presented as LS-Means ± SEM where
differences were considered significant when P <0.05.
Figures 5.7 A and 5.7 B demonstrate assay functionality showing CoCl2’s strong
proangiogenic effect on hVEGF-reporter upregulation (P<0.05). Both 10 µM E (Fig 5.7
A) and NE (Fig 5.7 B) increased (P<0.05) hVEGF-Luc reporter activity compared to
controls (media only). Propranolol and prazosin (1µM) [11, 12] are pharmacological
inhibitors of β and α adrenergic receptors respectively. Propranolol had no effect on E
stimulated hVEGF-Luc reporter activity, yet Prazosin completely inhibited E’s
stimulatory effect (Fig 5.7 A). These findings suggest that E’s angiogenic effect is
mediated through the αAR, while studies in other cell lines have shown the βAR to be
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responsible for E’s actions [10, 11, 29]. Additionally, NE’s stimulatory effect was not
completely blocked by either propranolol or prazosin but had a diminutive effect on
hVEGF-Luc activity. Like E, NE has been shown to act mainly through β ARs [10-12] to
induce its effect on VEGF. These results demonstrate the possibility of a more complex
regulation of VEGF in prostate cancer cells.
Conclusions
Both E and NE have previously demonstrated their effect on VEGF production in
similar studies [10-12], yet this study is unique in using a biophotonic model.
Additionally, to our knowledge this study is the first to show E induction of VEGF
upregulation in a prostate cancer cell line. Obviously, the psychophysiological
component of cancer progression will continue to be an area of important research due
the potential of therapy development and drug discovery.
The effectiveness of biophotonic tools such as the assay demonstrated here has
become an integral aspect of scientific discovery. Accurate and meaningful results in a
timely manner are paramount to the ever changing fast paced world of research. This
assay demonstrated the ability to effectively determine how the catecholamines, E and
NE effect VEGF production in a prostate cell line. Now future studies can be focused
towards the intricacies of this physiological response. This assay used in the manner
described in this paper has the potential to discover and unlock other angiogenic
phenomenon associated with a broad range of biological molecules and chemicals.
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CHAPTER VI
GENERAL CONCLUSIONS

The ubiquitous use of biophotonic models presents the need to verify the accuracy
of such models. The animal models used in these studies were in the least fine-tuned and
information concerning the efficacy of such models was obtained. The VEGFR-2-Luc
mouse has the potential to monitor VEGFR-2 gene activity in a wound healing
environment, although lacks the precision of measuring effects of the biological
compounds tested in this dissertation. This conclusion can be inferred by the data
presented in these studies. In hindsight, the tremendous variation in photonic emission
within each treatment group caused by individual animal variation may be reduced by
some form of randomization. Randomizing the animals according to the level of
photonic emission each individual produces could result in less variation within treatment
groups. This could possibly be achieved by measuring photonic emission coming from
the testes of the animals and dividing the mice into high signal and low signal groups. If
the variation could be reduced the models tested in these studies have the potential to
effectively monitor the compounds tested.
The cell based model discussed in this document provides a more precise and
efficient manner of monitoring compounds on the angiogenic system. Much is to learn
concerning the psychophysiological aspects of cancer. Therefore, more studies regarding
the precise details of how compounds such as catecholamines regulate the different facets
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of cancer formation and progression are needed. That said, this VEGF assay could be
utilized as a standalone VEGF gene transcription assay if the described protocol is
followed. Granted, this VEGF assay is specific to the prostate cancer system, but it still
possesses the potential to systematically identify various compounds possessing
angiogenic potential.

129

